<html lang="en" class="pb-page js" data-request-id="94d611ad83dbaf32-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d611ad83dbaf32-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/tMV9MOIFcsfLclFMlbzTF0q7kUtCQIbhvXzLcMQV5wFh5nFX_XtKlgb5QE5POza4g7W83XBEXrstSmwcAFvIpQ=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d611ad83dbaf32-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.32162983742626006"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Obstetrics/Gynecology General|Clinical Medicine General">
<meta name="Specialties" content="Obstetrics/Gynecology|Clinical Medicine"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa1904351","title":"Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids","category":"Research","type":"Original Article","topics":"Obstetrics/Gynecology General|Clinical Medicine General","specialties":"Obstetrics/Gynecology|Clinical Medicine","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2020-01-23T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Obstetrics/Gynecology General|Clinical Medicine General\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Obstetrics/Gynecology|Clinical Medicine\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa1904351","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d611ad83dbaf32-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids"><meta name="dc.Creator" content="William D. Schlaff"><meta name="dc.Creator" content="Ronald T. Ackerman"><meta name="dc.Creator" content="Ayman Al-Hendy"><meta name="dc.Creator" content="David F. Archer"><meta name="dc.Creator" content="Kurt T. Barnhart"><meta name="dc.Creator" content="Linda D. Bradley"><meta name="dc.Creator" content="Bruce R. Carr"><meta name="dc.Creator" content="Eve C. Feinberg"><meta name="dc.Creator" content="Sandra M. Hurtado"><meta name="dc.Creator" content="JinHee Kim"><meta name="dc.Creator" content="Ran Liu"><meta name="dc.Creator" content="R. Garn Mabey, Jr."><meta name="dc.Creator" content="Charlotte D. Owens"><meta name="dc.Creator" content="Alfred Poindexter"><meta name="dc.Creator" content="Elizabeth E. Puscheck"><meta name="dc.Creator" content="Henry Rodriguez-Ginorio"><meta name="dc.Creator" content="James A. Simon"><meta name="dc.Creator" content="Ahmed M. Soliman"><meta name="dc.Creator" content="Elizabeth A. Stewart"><meta name="dc.Creator" content="Nelson B. Watts"><meta name="dc.Creator" content="Ozgul Muneyyirci-Delale"><meta name="dc.Description" content="Uterine fibroids are hormone-responsive neoplasms that are associated with heavy menstrual bleeding. Elagolix, an oral gonadotropin-releasing hormone antagonist resulting in rapid, reversible suppr..."><meta name="Description" content="Uterine fibroids are hormone-responsive neoplasms that are associated with heavy menstrual bleeding. Elagolix, an oral gonadotropin-releasing hormone antagonist resulting in rapid, reversible suppr..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2020-01-23"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa1904351"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202001233820407"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="YXQYoa1904351"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2020 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa1904351">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa1904351">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa1904351">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids | NEJM">
        <meta property="og:title" content="Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa1904351">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/2b6cce23-d938-4741-a88a-3b75de357388/nejmoa1904351_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/2b6cce23-d938-4741-a88a-3b75de357388/nejmoa1904351_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Uterine fibroids are hormone-responsive neoplasms that are associated with heavy menstrual
bleeding. Elagolix, an oral gonadotropin-releasing hormone antagonist resulting in
rapid, reversible suppr...">
        <meta name="twitter:description" content="Uterine fibroids are hormone-responsive neoplasms that are associated with heavy menstrual
bleeding. Elagolix, an oral gonadotropin-releasing hormone antagonist resulting in
rapid, reversible suppr...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="1514">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa1904351">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa1904351">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;article:article:doi\:10.1056/NEJMoa1904351;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;issue:issue:doi\:10.1056/nejm_2020.382.issue-4;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1904351" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1904351" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1904351" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa1904351" class="inputDoi"><input type="hidden" value="W.D. Schlaff and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2020;382:328-340" class="inputCitation"><input type="hidden" value="01-22-2020" class="inputEPubDate"><input type="hidden" value="January 2020" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d611ad83dbaf32-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">William D.</span> <span property="familyName">Schlaff</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ronald T.</span> <span property="familyName">Ackerman</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ayman</span> <span property="familyName">Al-Hendy</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">David F.</span> <span property="familyName">Archer</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kurt T.</span> <span property="familyName">Barnhart</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Linda D.</span> <span property="familyName">Bradley</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Bruce R.</span> <span property="familyName">Carr</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+13</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Eve C.</span> <span property="familyName">Feinberg</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sandra M.</span> <span property="familyName">Hurtado</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">JinHee</span> <span property="familyName">Kim</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ran</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">R. Garn</span> <span property="familyName">Mabey</span>, Jr., <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Charlotte D.</span> <span property="familyName">Owens</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Alfred</span> <span property="familyName">Poindexter</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Elizabeth E.</span> <span property="familyName">Puscheck</span>, <span property="honorificSuffix">M.D., M.B.A.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Henry</span> <span property="familyName">Rodriguez-Ginorio</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">James A.</span> <span property="familyName">Simon</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ahmed M.</span> <span property="familyName">Soliman</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Elizabeth A.</span> <span property="familyName">Stewart</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Nelson B.</span> <span property="familyName">Watts</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-0719-9801" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-0719-9801</a></span></span>, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Ozgul</span> <span property="familyName">Muneyyirci-Delale</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-13</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">January 22, 2020</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2020<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">382</span></span>:<span property="pageStart">328</span>-<span property="pageEnd">340</span></div><div class="doi">DOI: 10.1056/NEJMoa1904351</div><div class="core-enumeration"><a href="/toc/nejm/382/4"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">382</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">4</span></span></a></div><div><a href="#tab-information">Copyright © 2020</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DWilliam%2BD.%2BSchlaff%252C%2BRonald%2BT.%2BAckerman%252C%2BAyman%2BAl-Hendy%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D382%26issueNum%3D4%26contentID%3D10.1056%252FNEJMoa1904351%26title%3DElagolix%2Bfor%2BHeavy%2BMenstrual%2BBleeding%2Bin%2BWomen%2Bwith%2BUterine%2BFibroids%26publicationDate%3D01%252F23%252F2020" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa1904351" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DWilliam%2BD.%2BSchlaff%252C%2BRonald%2BT.%2BAckerman%252C%2BAyman%2BAl-Hendy%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D382%26issueNum%3D4%26contentID%3D10.1056%252FNEJMoa1904351%26title%3DElagolix%2Bfor%2BHeavy%2BMenstrual%2BBleeding%2Bin%2BWomen%2Bwith%2BUterine%2BFibroids%26publicationDate%3D01%252F23%252F2020" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/3237e358-bd6f-420d-b041-782b6fe43c7d/nejmoa1904351.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa1904351.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa1904351" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa1904351" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1904351.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Uterine fibroids are hormone-responsive neoplasms that are associated with heavy menstrual bleeding. Elagolix, an oral gonadotropin-releasing hormone antagonist resulting in rapid, reversible suppression of ovarian sex hormones, may reduce fibroid-associated bleeding.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We conducted two identical, double-blind, randomized, placebo-controlled, 6-month phase 3 trials (Elaris Uterine Fibroids 1 and 2 [UF-1 and UF-2]) to evaluate the efficacy and safety of elagolix at a dose of 300 mg twice daily with hormonal “add-back” therapy (to replace reduced levels of endogenous hormones; in this case, estradiol, 1 mg, and norethindrone acetate, 0.5 mg, once daily) in women with fibroid-associated bleeding. An elagolix-alone group was included to assess the impact of add-back therapy on the hypoestrogenic effects of elagolix. The primary end point was menstrual blood loss of less than 80 ml during the final month of treatment and at least a 50% reduction in menstrual blood loss from baseline to the final month; missing data were imputed with the use of multiple imputation.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 412 women in UF-1 and 378 women in UF-2 underwent randomization, received elagolix or placebo, and were included in the analyses. Criteria for the primary end point were met in 68.5% of 206 women in UF-1 and in 76.5% of 189 women in UF-2 who received elagolix plus add-back therapy, as compared with 8.7% of 102 women and 10% of 94 women, respectively, who received placebo (P&lt;0.001 for both trials). Among the women who received elagolix alone, the primary end point was met in 84.1% of 104 women in UF-1 and in 77% of 95 women in UF-2. Hot flushes (in both trials) and metrorrhagia (in UF-1) occurred significantly more commonly with elagolix plus add-back therapy than with placebo. Hypoestrogenic effects of elagolix, especially decreases in bone mineral density, were attenuated with add-back therapy.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">Elagolix with add-back therapy was effective in reducing heavy menstrual bleeding in women with uterine fibroids. (Funded by AbbVie; Elaris UF-1 and Elaris UF-2 ClinicalTrials.gov numbers, <a href="http://clinicaltrials.gov/show/NCT02654054" target="_blank">NCT02654054</a> and <a href="http://clinicaltrials.gov/show/NCT02691494" target="_blank">NCT02691494</a>.)</div></section></section></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Uterine fibroids (leiomyomas), common noncancerous neoplasms of the uterus, are symptomatic in up to 50% of affected women.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2 r3 r4 r5" id="body-ref-r5-1" href-manipulated="true">1-5</a></sup> The primary symptom associated with uterine fibroids is heavy menstrual bleeding, which can lead to anemia.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6 r7 r8" id="body-ref-r8" href-manipulated="true">6-8</a></sup> Women with uterine fibroids can also have pelvic pain and pressure, urinary and gastrointestinal symptoms, infertility, and complications of pregnancy.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6 r9 r10 r11 r12" id="body-ref-r12" href-manipulated="true">6,9–12</a></sup> Uterine fibroids and their associated symptoms can have a major effect on a woman’s quality of life, psychological and social well-being, and overall health,<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13 r14 r15 r16 r17 r18" id="body-ref-r18-1" href-manipulated="true">13-18</a></sup> and they impose a substantial economic burden on women and society.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16 r17 r18" id="body-ref-r18-2" href-manipulated="true">16-18</a></sup></div><div role="paragraph">The primary management option for uterine fibroids is surgery, and hysterectomy is the most common intervention.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9 r11" id="body-ref-r11-2" href-manipulated="true">9,11</a></sup> Alternatives to surgery include oral contraceptives, progestins, tranexamic acid, and a variety of interventional therapies (e.g., uterine-artery embolization and magnetic resonance–guided focused ultrasonography).<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9 r19 r20 r21" id="body-ref-r21" href-manipulated="true">9,19–21</a></sup> However, data from randomized, controlled trials showing the effectiveness of these treatment options in women with symptomatic fibroids are limited.<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22" id="body-ref-r22-1" href-manipulated="true" aria-label="Reference 22">22</a></sup> Injectable depot formulations of gonadotropin-releasing hormone (GnRH) agonists are also prescribed for heavy menstrual bleeding associated with uterine fibroids; however, such treatments induce long-lasting gonadal suppression resulting in adverse hypoestrogenic effects.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6 r22 r23" id="body-ref-r23" href-manipulated="true">6,22,23</a></sup> Data show that coadministration with progestins (e.g., leuprolide acetate with medroxyprogesterone acetate) may attenuate these effects.<sup><a href="#core-r24" role="doc-biblioref" data-xml-rid="r24" id="body-ref-r24" href-manipulated="true" aria-label="Reference 24">24</a></sup> An oral option that provides long-term, safe, and effective management of heavy menstrual bleeding in women with uterine fibroids would be a useful alternative to existing therapies.</div><div role="paragraph">Elagolix is an oral, nonpeptide GnRH antagonist that results in rapid, reversible suppression of gonadotropins and ovarian sex hormones in women.<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25 r26 r27" id="body-ref-r27-1" href-manipulated="true">25-27</a></sup> These effects occur within 24 hours after the initiation of treatment and can be readily reversed on discontinuation of the drug, owing to its short half-life.<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25" id="body-ref-r25-2" href-manipulated="true" aria-label="Reference 25">25</a></sup> Elagolix is approved for the management of moderate-to-severe endometriosis-associated pain; when administered alone, it is associated with hypoestrogenic effects such as decreased bone mineral density and vasomotor symptoms that are consistent with its mechanism of action.<sup><a href="#core-r27" role="doc-biblioref" data-xml-rid="r27" id="body-ref-r27-2" href-manipulated="true" aria-label="Reference 27">27</a></sup> In a phase 2b study involving women with uterine fibroids, elagolix at a total daily dose of 600 mg with and without hormonal “add-back” therapy (to replace reduced levels of endogenous hormones) was effective in reducing menstrual bleeding and had a favorable safety profile. Add-back therapy attenuated decreases in bone mineral density and other hypoestrogenic effects, as observed in other studies.<sup><a href="#core-r28" role="doc-biblioref" data-xml-rid="r28 r29" id="body-ref-r29-1" href-manipulated="true">28,29</a></sup></div><div role="paragraph">We report the results of two identical, double-blind, randomized, placebo-controlled, 6-month phase 3 trials, Elaris Uterine Fibroids 1 and 2 (UF-1 and UF-2). The objective of both trials was to assess the efficacy and safety of elagolix with add-back therapy, as compared with placebo, in the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. We also assessed hypoestrogenic effects in women who received elagolix with add-back therapy, as compared with elagolix alone.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design and Oversight</h3><div role="paragraph">UF-1 was conducted at 76 sites in the United States (including Puerto Rico) from December 2015 through December 2018, and UF-2 was conducted at 77 sites in the United States and Canada from February 2016 through January 2019. UF-1 and UF-2 were registered separately, and therefore the results are reported individually in this article. One patient in UF-1 and three patients in UF-2 who underwent randomization were enrolled before the trial registration date on ClinicalTrials.gov because of administrative error.</div><div role="paragraph">Each trial consisted of a period of washout of hormonal medication (if applicable) (Table S1 in the <a href="#ap2">Supplementary Appendix</a>, available with the full text of this article at NEJM.org), a screening period of 2.5 to 3.5 months, a 6-month treatment period, and a 12-month follow-up period (or a corresponding extension study) (Fig. S1). Results of the 6-month treatment period are reported here.</div><div role="paragraph">Women were randomly assigned within 10 days after the start of their menses by means of an interactive response technology system in a 2:1:1 ratio to receive elagolix at a dose of 300 mg twice daily with add-back therapy (estradiol, 1 mg, and norethindrone acetate, 0.5 mg, once daily), elagolix at a dose of 300 mg twice daily alone, or placebo in a matched, double-blind, double-dummy manner. Women who received elagolix alone were included as a reference group to characterize the effects of add-back therapy.</div><div role="paragraph">The trials were conducted in accordance with the guidelines of the International Council for Harmonisation and applicable regulations and ethical principles of the Declaration of Helsinki. The study protocols were approved by the Schulman Institutional Review Board for central sites and by an institutional review board, ethics committee, or both for all other trial sites. All the women provided written informed consent. The trial sponsor, AbbVie, designed the trials and held and analyzed the data; the investigators and the sponsor jointly conducted the trials and gathered and interpreted the data. All the authors had full access to the data, signed confidentiality agreements with the sponsor regarding the data, and vouch for the completeness and accuracy of the data and analyses and for the fidelity of the trial to the <a href="#ap1">protocol</a>, available at NEJM.org. The first draft of the manuscript was written by medical writers employed by the sponsor, with input from all the authors. All the authors critically reviewed and provided feedback on all subsequent versions of the manuscript and, along with the sponsor, made the decision to submit the manuscript for publication.</div></section><section id="sec-1-2"><h3>Patients</h3><div role="paragraph"><a id="exam-tint-one-a"></a><a id="exam-tint-one-b"></a><a id="exam-tint-one-c"></a><a id="exam-tint-one-d"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">Eligible participants were premenopausal women who were between the ages of 18 and 51 years at the time of screening and who had an ultrasonography-confirmed diagnosis of uterine fibroids and heavy menstrual bleeding, as defined by more than 80 ml of menstrual blood loss per menstrual cycle for at least two separate cycles. Menstrual blood loss was measured by the alkaline hematin method, which objectively quantified the amount of blood in sanitary products collected (Supplemental Methods section 1D in the <a href="#ap2">Supplementary Appendix</a>).</span><sup><a href="#core-r30" role="doc-biblioref" data-xml-rid="r30" id="body-ref-r30" href-manipulated="true" aria-label="Reference 30">30</a></sup> Women were excluded if they were pregnant or if they had a persistent or complex ovarian cyst, cancer, pelvic inflammatory disease, a history of osteoporosis, or a bone mineral density T score of −1.5 or less at the lumbar spine, total hip, or femoral neck.</div></section><section id="sec-1-3"><h3>Assessments and End Points</h3><div role="paragraph"><span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">All bleeding end points were assessed by means of the alkaline hematin method during the screening and treatment periods.</span> If a woman did not return any used sanitary products at any visit during the treatment period, she was asked a standardized question to determine whether she had had any bleeding or spotting since her last trial visit. If no bleeding was reported over an interval, the menstrual blood loss over the interval was counted as zero. Safety evaluations included the assessment of adverse events, bone mineral density, lipid and liver profiles, endometrial thickness and biopsy results, ovarian cysts, and pregnancy (Supplemental Methods section 1E).</div><div role="paragraph"><a id="exam-tint-two-a"></a><a id="exam-tint-two-b"></a><a id="exam-tint-two-c"></a><a id="exam-tint-two-d"></a><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="two-a two-b two-c two-d">The primary end point was menstrual blood loss of less than 80 ml during the final month and at least a 50% reduction in menstrual blood loss from baseline to the final month.</span> Women who met these two criteria but who had prematurely discontinued elagolix or placebo owing to adverse events or lack of efficacy or who had undergone surgery or invasive intervention for uterine fibroids during the trial were categorized as not having met the criteria for the primary end point.</div><div role="paragraph">Ranked secondary end points in hierarchical order were the following: the change from baseline in menstrual blood loss at the final month; the percentage of women who had suppression of bleeding (not accounting for spotting) at the final month; the change from baseline in menstrual blood loss at 6 months; the change from baseline in menstrual blood loss at 3 months; the percentage of women with a baseline hemoglobin level of 10.5 g per deciliter or less who had an increase in the hemoglobin level of more than 2 g per deciliter at 6 months; and the change from baseline in menstrual blood loss at 1 month. Other prespecified efficacy end points are listed in Table S2. Women were also asked to report their symptoms over the previous 4 weeks on the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire. This questionnaire includes a symptom severity score (scores range from 0 to 100, with higher scores indicating increased severity) and a health-related quality-of-life total score that is the sum of scores on six subscales (concern, activities, energy and mood, control, self-consciousness, and sexual function). Scores on the health-related quality-of-life portion of the questionnaire range from 0 to 100, with higher scores indicating a better quality of life.<sup><a href="#core-r31" role="doc-biblioref" data-xml-rid="r31" id="body-ref-r31" href-manipulated="true" aria-label="Reference 31">31</a></sup></div></section><section id="sec-1-4"><h3>Statistical Analysis</h3><div role="paragraph">For each trial, we calculated that a sample of approximately 400 women would provide at least 90% power with a 0.05 two-sided significance level to detect a difference between the group of women who received elagolix with add-back therapy and the placebo group in the primary end point, assuming response rates of 60% among the women who received elagolix with add-back therapy and 30% in the placebo group, based on results from a previous phase 2b study of elagolix.<sup><a href="#core-r32" role="doc-biblioref" data-xml-rid="r32" id="body-ref-r32" href-manipulated="true" aria-label="Reference 32">32</a></sup> Efficacy and safety analyses were performed in all the women who underwent randomization and received at least one dose of elagolix or placebo, including those who prematurely discontinued elagolix or placebo or withdrew consent. We performed primary efficacy comparisons between the group of women who received elagolix with add-back therapy and the placebo group; we did not perform efficacy comparisons between the group of women who received elagolix with add-back therapy and those who received elagolix alone. Comparisons between the two elagolix groups were limited to evaluating changes in bone mineral density.</div><div role="paragraph">All statistical tests were performed with the use of SAS software (version 9.4), with a 0.05 two-sided significance level and 95% confidence interval. The baseline value for menstrual blood loss was defined as the mean of the total menstrual blood loss from all used sanitary products returned during all qualified menstrual cycles before or on trial day 1. Baseline for all other variables was defined as the last nonmissing measurement obtained before or on trial day 1, unless otherwise specified. For all women who underwent randomization and received treatment, the final month was defined as the last 28 days before and including the last treatment period visit date (if data on menstrual blood loss [measured with the use of the alkaline hematin method] that could be evaluated were available between the last treatment period visit date and the last dose date, then the last dose date was used). Missing data on menstrual blood loss in the final month were imputed with the use of multiple imputation (Supplemental Methods section 1F).</div><div role="paragraph">The primary end point was analyzed with the use of a logistic-regression model with treatment as the main effect and baseline menstrual blood loss as a covariate. For ranked secondary end points, the change in menstrual blood loss from baseline to the final month was based on data from multiple imputation for the primary efficacy analysis and analyzed with the use of a one-way analysis of covariance model with treatment as the main effect and baseline menstrual blood loss as a covariate. Changes in observed menstrual blood loss from baseline to 1, 3, and 6 months were analyzed with the use of a mixed model for repeated measures, with the fixed categorical effects of treatment, month, and treatment-by-month interaction and the continuous fixed covariate of baseline menstrual blood loss. The percentage of women who had suppression of bleeding at the final month and the percentage of women with a baseline hemoglobin level of 10.5 g per deciliter or less who had an increase in the hemoglobin level of more than 2 g per deciliter at 6 months were each analyzed with the use of a Pearson’s chi-square test or Fisher’s exact test (if ≥20% of the cells in the categorical table had expected counts of &lt;5). The change from baseline to 6 months in the variables of the UFS-QOL questionnaire was analyzed with the use of an analysis of covariance model, with treatment as the main effect and baseline value as a covariate. Other results, including results of the sensitivity analyses for the primary end point and safety analyses, are provided in Supplemental Methods sections 1F and 1G.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patients</h3><div role="paragraph">A total of 413 women in UF-1 and 378 in UF-2 underwent randomization; all but 1 woman in UF-1 received elagolix or placebo and were included in the efficacy and safety analyses. Of the women who underwent randomization and received elagolix or placebo, 328 in UF-1 (79.6%) and 289 in UF-2 (76.5%) completed the 6-month treatment period. Similar percentages of women prematurely discontinued treatment across all trial groups (Fig. S1). <a href="#t1">Table 1</a> summarizes the baseline characteristics of the patients.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1904351_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1904351_t1.jpg"><img src="/cms/10.1056/NEJMoa1904351/asset/5ebf2fc3-378a-4473-80db-3133143aefa2/assets/images/large/nejmoa1904351_t1.jpg" height="1869" width="1435" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="3"><span>Elaris UF-1</span></th><th class="txxr-borders" colspan="3"><span>Elaris UF-2</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Placebo<br> (N=102)</th><th class="xxxx-borders">Elagolix Alone<br> (N=104)</th><th class="xxxx-borders">Elagolix with<br> Add-Back<br> Therapy<br> (N=206)</th><th class="xxxx-borders">Placebo<br> (N=94)</th><th class="xxxx-borders">Elagolix Alone<br>(N=95)</th><th class="xxxr-borders">Elagolix with<br> Add-Back<br> Therapy<br> (N=189)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Age — yr</td><td class="xxxx-borders shading">41.6±5.7</td><td class="xxxx-borders shading">42.6±5.2</td><td class="xxxx-borders shading">42.6±5.3</td><td class="xxxx-borders shading">42.5±5.4</td><td class="xxxx-borders shading">42.2±5.4</td><td class="xxxr-borders shading">42.5±5.3</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Race — no./total no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">70/102 (68.6)</td><td class="xxxx-borders shading">69/103 (67.0)</td><td class="xxxx-borders shading">141/206 (68.4)</td><td class="xxxx-borders shading">63/94 (67)</td><td class="xxxx-borders shading">66/95 (69)</td><td class="xxxr-borders shading">124/188 (66.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">30/102 (29.4)</td><td class="xxxx-borders">27/103 (26.2)</td><td class="xxxx-borders">59/206 (28.6)</td><td class="xxxx-borders">30/94 (32)</td><td class="xxxx-borders">27/95 (28)</td><td class="xxxr-borders">59/188 (31.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Other</td><td class="xxxx-borders shading">2/102 (2.0)</td><td class="xxxx-borders shading">7/103 (6.8)</td><td class="xxxx-borders shading">6/206 (3.0)</td><td class="xxxx-borders shading">1/94 (1)</td><td class="xxxx-borders shading">2/95 (2)</td><td class="xxxr-borders shading">5/188 (2.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Missing data</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Body-mass index<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">33.8±7.7</td><td class="xxxx-borders shading">33.4±7.7</td><td class="xxxx-borders shading">33.3±6.8<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">33.8±7.2</td><td class="xxxx-borders shading">34.5±7.9</td><td class="xxxr-borders shading">33.2±6.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Menstrual blood loss/menstrual cycle — ml</td><td class="xxxx-borders">255.3±174.0</td><td class="xxxx-borders">248.9±169.6</td><td class="xxxx-borders">238.0±150.1</td><td class="xxxx-borders">254.3±178.5</td><td class="xxxx-borders">224.9±146.2</td><td class="xxxr-borders">228.5±148.8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Hemoglobin level — g/dl</td><td class="xxxx-borders shading">11.0±1.4</td><td class="xxxx-borders shading">10.6±1.5</td><td class="xxxx-borders shading">11.1±1.5</td><td class="xxxx-borders shading">11.0±1.6</td><td class="xxxx-borders shading">11.0±1.6</td><td class="xxxr-borders shading">11.1±1.5</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Uterine volume — cm<sup>3</sup></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Measured with TAU or TVU</td><td class="xxxx-borders shading">478.1±356.9</td><td class="xxxx-borders shading">499.6±437.9</td><td class="xxxx-borders shading">474.9±388.2</td><td class="xxxx-borders shading">549.6± 452.1</td><td class="xxxx-borders shading">537.3±521.9</td><td class="xxxr-borders shading">496.1±381.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Measured with MRI<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">561.9±437.2</td><td class="xxxx-borders">617.0±582.3</td><td class="xxxx-borders">508.6±342.2</td><td class="xxxx-borders">798.6±730.9</td><td class="xxxx-borders">675.7±906.2</td><td class="xxxr-borders">676.8±559.1</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Average fibroid volume — cm<sup>3</sup></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Measured with TAU or TVU<a href="#t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">52.1±72.2</td><td class="xxxx-borders">44.2±64.2</td><td class="xxxx-borders">52.0±69.7</td><td class="xxxx-borders">73.3±100.4</td><td class="xxxx-borders">67.4±132.3</td><td class="xxxr-borders">57.3±104.8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Measured with MRI<a href="#t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">73.1±98.1</td><td class="xxxx-borders shading">60.2±70.3</td><td class="xxxx-borders shading">66.0±73.7</td><td class="xxxx-borders shading">104.3±120.5</td><td class="xxxx-borders shading">83.3±130.8</td><td class="xxxr-borders shading">72.0±68.2</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">UFS-QOL score<a href="#t1fn8" role="doc-noteref">††</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Symptom severity score<a href="#t1fn9" role="doc-noteref">‡‡</a></td><td class="xxxx-borders shading">61.7±19.2</td><td class="xxxx-borders shading">60.4±22.5</td><td class="xxxx-borders shading">57.3±22.2</td><td class="xxxx-borders shading">60.5±23.4</td><td class="xxxx-borders shading">63.7±20.4</td><td class="xxxr-borders shading">60.9±21.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Health-related quality-of-life total score<a href="#t1fn10" role="doc-noteref">§§</a></td><td class="xxxx-borders">40.7±20.3</td><td class="xxxx-borders">42.5±23.3</td><td class="xxxx-borders">44.1±23.5</td><td class="xxxx-borders">43.0±22.8</td><td class="xxxx-borders">42.2±24.0</td><td class="xxxr-borders">43.3±24.2</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Bone mineral density z score</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Lumbar spine</td><td class="xxxx-borders">0.9±1.0</td><td class="xxxx-borders">1.1±1.2</td><td class="xxxx-borders">1.0±1.0<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">1.1±1.1</td><td class="xxxx-borders">0.9±1.2</td><td class="xxxr-borders">1.1±1.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Total hip</td><td class="xxxx-borders shading">0.7±0.9</td><td class="xxxx-borders shading">0.8±0.9</td><td class="xxxx-borders shading">0.8±0.9<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">0.7±1.0</td><td class="xxxx-borders shading">0.8±1.0</td><td class="xxxr-borders shading">0.8±0.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Femoral neck</td><td class="xbxx-borders">0.5±0.8</td><td class="xbxx-borders">0.6±0.9</td><td class="xbxx-borders">0.6±0.9<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xbxx-borders">0.6±0.9</td><td class="xbxx-borders">0.6±0.9</td><td class="xbxr-borders">0.6±0.9</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plus–minus values are means ±SD. MRI denotes magnetic resonance imaging, TAU transabdominal ultrasonography, and TVU transvaginal ultrasonography.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Race was reported by the women.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">Data shown are for 205 patients.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">For the Elaris UF-1 trial, data shown are for 48 patients who received placebo, 51 patients who received elagolix alone, and 96 patients who received elagolix with add-back therapy. For the Elaris UF-2 trial, data shown are for 51 patients who received placebo, 52 patients who received elagolix alone, and 89 patients who received elagolix with add-back therapy.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t1fn6" role="paragraph">For the Elaris UF-1 trial, data shown are for 100 patients who received placebo, 102 patients who received elagolix alone, and 203 patients who received elagolix with add-back therapy. For the Elaris UF-2 trial, data shown are for 92 patients who received placebo, 95 patients who received elagolix alone, and 186 patients who received elagolix with add-back therapy.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t1fn7" role="paragraph">For the Elaris UF-1 trial, data shown are for 47 patients who received placebo, 45 patients who received elagolix alone, and 83 patients who received elagolix with add-back therapy. For the Elaris UF-2 trial, data shown are for 45 patients who received placebo, 52 patients who received elagolix alone, and 92 patients who received elagolix with add-back therapy.</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="t1fn8" role="paragraph">On the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire, scores for symptom severity range from 0 to 100, with higher scores indicating increased severity. Total scores for health-related quality of life range from 0 to 100, with higher scores indicating a better quality of life.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡‡</div><div id="t1fn9" role="paragraph">For the Elaris UF-1 trial, data shown are for 102 patients who received placebo, 103 patients who received elagolix alone, and 206 patients who received elagolix with add-back therapy. For the Elaris UF-2 trial, data shown are for 92 patients who received placebo, 94 patients who received elagolix alone, and 186 patients who received elagolix with add-back therapy.</div></div><div role="doc-footnote" data-has="label"><div class="label">§§</div><div id="t1fn10" role="paragraph">For the Elaris UF-1 trial, data shown are for 102 patients who received placebo, 103 patients who received elagolix alone, and 206 patients who received elagolix with add-back therapy. For the Elaris UF-2 trial, data shown are for 90 patients who received placebo, 94 patients who received elagolix alone, and 185 patients who received elagolix with add-back therapy.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Primary Efficacy End Point</h3><div role="paragraph"><span id="tint4" class="named-content" data-type="exam-tint" data-answer-ids="two-a two-b two-c two-d">In the primary efficacy analysis with multiple imputation for missing data, significantly greater percentages of women who received elagolix with add-back therapy (68.5% of 206 women in UF-1 and 76.5% of 189 women in UF-2) met the criteria for the primary end point, as compared with women who received placebo (8.7% of 102 women in UF-1 and 10% of 94 women in UF-2) (P&lt;0.001 for the two trials) (<a href="#f1">Figure 1</a>).</span> Among women who received elagolix alone, 84.1% of 104 women in UF-1 and 77% of 95 women in UF-2 met the criteria for the primary end point. Results of all sensitivity analyses of the primary end point were similar to those of the primary analysis (Table S3).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1904351_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1904351_f1.jpg"><img src="/cms/10.1056/NEJMoa1904351/asset/2b6cce23-d938-4741-a88a-3b75de357388/assets/images/large/nejmoa1904351_f1.jpg" height="1514" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Reduction in Heavy Menstrual Bleeding in Women with Uterine Fibroids.</div><div class="notes"><div role="doc-footnote">Shown are the percentages of women who met the criteria for the primary end point (a menstrual blood loss [MBL] volume of &lt;80 ml in the final month and a ≥50% reduction in MBL volume from baseline to the final month) in the two trials. A significantly greater percentage of women who received elagolix with add-back therapy met the criteria for the primary end point than women who received placebo. The final month was defined as the last 28 days before and including the last treatment period visit date (if data on menstrual blood loss [measured with the use of the alkaline hematin method] that could be evaluated were available between the last treatment period visit date and the last dose date, then the last dose date was used). CI denotes confidence interval.</div></div></figcaption></figure></div></section><section id="sec-2-3"><h3>Ranked Secondary and Other Efficacy End Points</h3><div role="paragraph">Elagolix with add-back therapy, as compared with placebo, resulted in significant improvements in the prespecified ranked secondary outcomes: a greater reduction in menstrual blood loss from baseline to the final month, a higher percentage of women with suppression of bleeding at the final month, a greater reduction in menstrual blood loss from baseline to 6 months and 3 months, a higher percentage of women with a baseline hemoglobin level of 10.5 g per deciliter or less who had an increase in the hemoglobin level of more than 2 g per deciliter at 6 months, and a greater reduction in menstrual blood loss from baseline to 1 month (<a href="#t2">Table 2</a>). (Reductions in menstrual blood loss over time are shown in Figure S2.) In the group of women who received elagolix with add-back therapy, 48.1% in UF-1 and 52.9% in UF-2 had amenorrhea (no bleeding or spotting) in the final month (as compared with 4% and 5%, respectively, in the placebo group); the same percentages of women also had control of bleeding (≤1 day of spotting) in the final month (Table S4). (Results of measures of hemoglobin, uterine volume, and average fibroid volume are shown in Figures S3 through S5.)</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1904351_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1904351_t2.jpg"><img src="/cms/10.1056/NEJMoa1904351/asset/61f9ac7a-58cb-4588-963c-10cf446f6c62/assets/images/large/nejmoa1904351_t2.jpg" height="2004" width="1879" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders" colspan="3"><span>Elaris UF-1</span></th><th class="txxr-borders" colspan="3"><span>Elaris UF-2</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Placebo<br> (N=102)</th><th class="xxxx-borders">Elagolix Alone<br>(N=104)</th><th class="xxxx-borders">Elagolix with Add-Back Therapy<br> (N=206)</th><th class="xxxx-borders">Placebo<br> (N=94)</th><th class="xxxx-borders">Elagolix Alone<br> (N=95)</th><th class="xxxr-borders">Elagolix with Add-Back Therapy<br>(N=189)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Volume of menstrual blood loss at final mo — ml<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of women with data</td><td class="xxxx-borders">102</td><td class="xxxx-borders">104</td><td class="xxxx-borders">206</td><td class="xxxx-borders">94</td><td class="xxxx-borders">95</td><td class="xxxr-borders">189</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Change from baseline — least-squares mean (95% CI)</td><td class="xxxx-borders shading">0.8<br> (−28.3 to 30.0)</td><td class="xxxx-borders shading">−221.5<br> (−249.9 to −193.1)</td><td class="xxxx-borders shading">−176.7<br> (−197.1 to −156.3)</td><td class="xxxx-borders shading">−4.3<br> (−34.5 to 26.0)</td><td class="xxxx-borders shading">−198.8<br> (−229.0 to −168.5)</td><td class="xxxr-borders shading">−168.8<br> (−189.8 to −147.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Difference from placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">−222.3<br> (−263.0 to −181.6)</td><td class="xxxx-borders">−177.5<br> (−213.3 to −141.7)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">−194.5<br> (−237.1 to −152.0)</td><td class="xxxr-borders">−164.6<br> (−201.5 to −127.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">P value<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&lt;0.001</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Suppression of bleeding during final mo<a href="#t2fn2" role="doc-noteref">†</a><a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Women with suppression — no./total no. (%)</td><td class="xxxx-borders shading">4/91 (4)</td><td class="xxxx-borders shading">79/94 (84)</td><td class="xxxx-borders shading">104/183 (56.8)</td><td class="xxxx-borders shading">4/85 (5)</td><td class="xxxx-borders shading">72/81 (89)</td><td class="xxxr-borders shading">105/172 (61.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Difference from placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">79.6<br> (71.13 to 88.16)</td><td class="xxxx-borders">52.4<br> (44.11 to 60.76)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">84.2<br> (75.99 to 92.37)</td><td class="xxxr-borders">56.3<br> (47.77 to 64.91)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">P value<a href="#t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&lt;0.001</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Volume of menstrual blood loss at 6 mo — ml</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of women with data</td><td class="xxxx-borders shading">71</td><td class="xxxx-borders shading">67</td><td class="xxxx-borders shading">132</td><td class="xxxx-borders shading">64</td><td class="xxxx-borders shading">53</td><td class="xxxr-borders shading">124</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Change from baseline — least-squares mean (95% CI)</td><td class="xxxx-borders">−2.3<br> (−28.9 to 24.4)</td><td class="xxxx-borders">−236.2<br> (−263.3 to −209.2)</td><td class="xxxx-borders">−194.7<br> (−214.0 to −175.5)</td><td class="xxxx-borders">28.5<br> (−4.3 to 61.4)</td><td class="xxxx-borders">−223.7<br> (−259.1 to −188.3)</td><td class="xxxr-borders">−198.1<br> (−221.5 to −174.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Difference from placebo (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">−234.0<br> (−271.9 to −196.1)</td><td class="xxxx-borders shading">−192.5<br> (−225.3 to −159.6)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">−252.3<br> (−300.6 to −204.0)</td><td class="xxxr-borders shading">−226.6<br> (−267.0 to −186.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">P value<a href="#t2fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Volume of menstrual blood loss at 3 mo — ml</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of women with data</td><td class="xxxx-borders">85</td><td class="xxxx-borders">83</td><td class="xxxx-borders">172</td><td class="xxxx-borders">78</td><td class="xxxx-borders">72</td><td class="xxxr-borders">157</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Change from baseline — least-squares mean (95% CI)</td><td class="xxxx-borders shading">6.1<br> (−24.1 to 36.2)</td><td class="xxxx-borders shading">−234.7<br> (−265.0 to −204.5)</td><td class="xxxx-borders shading">−192.2<br> (−213.4 to −170.9)</td><td class="xxxx-borders shading">−14.2<br> (−37.0 to 8.6)</td><td class="xxxx-borders shading">−211.1<br> (−234.6 to −187.6)</td><td class="xxxr-borders shading">−200.3<br> (−216.4 to −184.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Difference from placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">−240.8<br> (−283.5 to −198.1)</td><td class="xxxx-borders">−198.2<br> (−235.1 to −161.3)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">−196.9<br> (−229.7 to −164.1)</td><td class="xxxr-borders">−186.1<br> (−214.0 to −158.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">P value<a href="#t2fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&lt;0.001</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Women with baseline hemoglobin level ≤10.5 g/dl and increase from baseline of &gt;2 g/dl at 6 mo</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Percentage of women — no./total no. (%)</td><td class="xxxx-borders shading">5/31 (16)</td><td class="xxxx-borders shading">27/41 (66)</td><td class="xxxx-borders shading">32/52 (62)</td><td class="xxxx-borders shading">5/24 (21)</td><td class="xxxx-borders shading">10/25 (40)</td><td class="xxxr-borders shading">24/48 (50)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Difference from placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">49.7<br> (30.27 to 69.18)</td><td class="xxxx-borders">45.4<br> (26.90 to 63.92)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">19.2<br> (−6.0 to 44.3)</td><td class="xxxr-borders">29.2<br> (7.6 to 50.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">P value<a href="#t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">0.02</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Volume of menstrual blood loss at 1 mo — ml</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of women with data</td><td class="xxxx-borders shading">95</td><td class="xxxx-borders shading">97</td><td class="xxxx-borders shading">187</td><td class="xxxx-borders shading">88</td><td class="xxxx-borders shading">83</td><td class="xxxr-borders shading">175</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Change from baseline — least-squares mean (95% CI)</td><td class="xxxx-borders">−19.0<br> (−50.6 to 12.6)</td><td class="xxxx-borders">−209.0<br> (−240.3 to −177.8)</td><td class="xxxx-borders">−135.2<br> (−157.6 to −112.7)</td><td class="xxxx-borders">−2.1<br> (−30.2 to 26.1)</td><td class="xxxx-borders">−196.6<br> (−225.6 to −167.6)</td><td class="xxxr-borders">−127.0<br> (−146.9 to −107.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Difference from placebo (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">−190.0<br> (−234.5 to −145.6)</td><td class="xxxx-borders shading">−116.2<br> (−154.9 to −77.4)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">−194.5<br> (−235.0 to −154.1)</td><td class="xxxr-borders shading">−125.0<br> (−159.5 to −90.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">P value<a href="#t2fn6" role="doc-noteref">‖</a></td><td class="xbxx-borders">&nbsp;</td><td class="xbxx-borders">&nbsp;</td><td class="xbxx-borders">&lt;0.001</td><td class="xbxx-borders">&nbsp;</td><td class="xbxx-borders">&nbsp;</td><td class="xbxr-borders">&lt;0.001</td></tr></tbody></table></div><figcaption><div class="caption">Key Secondary Efficacy End Points.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Outcomes are listed in the order of hierarchical statistical testing.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">The final month was defined as the last 28 days before and including the last treatment period visit date. If data on menstrual blood loss (measured with the use of the alkaline hematin method) that could be evaluated were available between the last treatment period visit date and the last dose date, then the last dose date was used. The missing data on menstrual blood loss in the final month were imputed with the use of multiple imputation.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">The P value was based on an analysis of covariance model with treatment as the main effect and baseline volume of menstrual blood loss as a covariate in each data set from multiple imputation.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t2fn4" role="paragraph">Suppression of bleeding indicated no bleeding, although there may have been spotting.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t2fn5" role="paragraph">The P value was based on the chi-square test (or Fisher’s exact test if ≥20% of the cells in the categorical table had an expected cell count of &lt;5).</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t2fn6" role="paragraph">The P value was based on a mixed model for repeated measures with treatment, month, and an interaction between treatment and month as fixed-effect factors and baseline volume of menstrual blood loss as a covariate in the comparison of each elagolix-with-add-back group with placebo.</div></div></div></figcaption></figure></div><div role="paragraph">On the UFS-QOL questionnaire, scores for symptom severity range from 0 to 100, with higher scores indicating increased severity. The least-squares mean (±SE) change in symptom severity from baseline to 6 months in women who received elagolix with add-back therapy was −33.2±1.61 in UF-1 and −41.4±1.60 in UF-2 (as compared with −10.3±2.25 and −7.9±2.28, respectively, in women who received placebo). On the health-related quality of life total score portion of the questionnaire, scores range from 0 to 100, with higher scores indicating a better quality of life. The least-squares mean (±SE) change in women who received elagolix with add-back therapy was 38.0±1.62 in UF-1 and 42.0±1.62 in UF-2 (as compared with 10.9±2.27 and 6.5±2.32, respectively, in women who received placebo) (Fig. S6).</div></section><section id="sec-2-4"><h3>Safety</h3><div role="paragraph">More than 60% of the women in each trial group reported at least one adverse event. The incidence of any adverse event was significantly higher among women who received elagolix alone in UF-1 (P&lt;0.001) and among those who received elagolix plus add-back therapy in UF-2 (P&lt;0.05) than among those who received placebo (<a href="#t3">Table 3</a>). Most adverse events were considered by the investigators to be mild or moderate in severity. Serious and severe adverse events are listed in Tables S5 and S6, respectively. <a id="exam-tint-three-b"></a><span id="tint5" class="named-content" data-type="exam-tint" data-answer-ids="three-b">All serious adverse events that were reported in the elagolix groups were resolved by the end of the trial.</span> Hot flushes were significantly more common with elagolix plus add-back therapy (20.4% and 19.6%, respectively, in UF-1 and UF-2) and elagolix alone (64.4% and 43%) than with placebo (8.8% and 4%); in UF-1 and UF-2, night sweats were significantly more common with elagolix alone (26.9% and 25%, respectively) than with placebo (2.9% and 5%, respectively) (<a href="#t3">Table 3</a>). Details regarding the severity profiles of hot flushes and night sweats each month and for the entire treatment course are shown in Table S7 and Figure S7. In addition, in UF-1, metrorrhagia was significantly more common among women who received elagolix plus add-back therapy than among those who received placebo (6.3% vs. 0%). No deaths were reported during the treatment period in either trial. Two pregnancies in the placebo group (one live birth and one spontaneous abortion) and one in the elagolix-alone group (an ectopic pregnancy) were reported during the treatment period in the two trials (Table S8).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1904351_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1904351_t3.jpg"><img src="/cms/10.1056/NEJMoa1904351/asset/9a47bb06-ed79-4d84-a79f-5572e2b9c5c2/assets/images/large/nejmoa1904351_t3.jpg" height="1424" width="1435" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders" colspan="3"><span>Elaris UF-1</span></th><th class="txxr-borders" colspan="3"><span>Elaris UF-2</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Placebo<br> (N=102)</th><th class="xxxx-borders">Elagolix Alone<br> (N=104)</th><th class="xxxx-borders">Elagolix with Add-Back Therapy<br> (N=206)</th><th class="xxxx-borders">Placebo<br> (N=94)</th><th class="xxxx-borders">Elagolix Alone<br> (N=95)</th><th class="xxxr-borders">Elagolix with Add-Back Therapy<br> (N=189)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="6"><span>number (percent)</span></th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Adverse events</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Any adverse event</td><td class="xxxx-borders">71 (69.6)</td><td class="xxxx-borders">94 (90.4)<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">140 (68.0)</td><td class="xxxx-borders">59 (63)</td><td class="xxxx-borders">72 (76)</td><td class="xxxr-borders">143 (75.7)<a href="#t3fn3" role="doc-noteref">‡</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Any serious adverse event<a href="#t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">5 (4.9)</td><td class="xxxx-borders shading">3 (2.9)</td><td class="xxxx-borders shading">3 (1.5)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">4 (4)</td><td class="xxxr-borders shading">7 (3.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Any severe adverse event<a href="#t3fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">4 (3.9)</td><td class="xxxx-borders">9 (8.7)</td><td class="xxxx-borders">19 (9.2)</td><td class="xxxx-borders">6 (6)</td><td class="xxxx-borders">11 (12)</td><td class="xxxr-borders">17 (9.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Any adverse event leading to trial-drug discontinuation</td><td class="xxxx-borders shading">8 (7.8)</td><td class="xxxx-borders shading">10 (9.6)</td><td class="xxxx-borders shading">22 (10.7)</td><td class="xxxx-borders shading">5 (5)</td><td class="xxxx-borders shading">12 (13)</td><td class="xxxr-borders shading">16 (8.5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging01"><b>Adverse events in ≥5% of women who received elagolix with add-back therapy in either trial</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Hot flushes</td><td class="xxxx-borders shading">9 (8.8)</td><td class="xxxx-borders shading">67 (64.4)<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">42 (20.4)<a href="#t3fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">4 (4)</td><td class="xxxx-borders shading">41 (43)<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxr-borders shading">37 (19.6)<a href="#t3fn2" role="doc-noteref">†</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Nausea</td><td class="xxxx-borders">10 (9.8)</td><td class="xxxx-borders">7 (6.7)</td><td class="xxxx-borders">23 (11.2)</td><td class="xxxx-borders">9 (10)</td><td class="xxxx-borders">4 (4)</td><td class="xxxr-borders">14 (7.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Headache</td><td class="xxxx-borders shading">9 (8.8)</td><td class="xxxx-borders shading">17 (16.3)</td><td class="xxxx-borders shading">17 (8.3)</td><td class="xxxx-borders shading">5 (5)</td><td class="xxxx-borders shading">13 (14)</td><td class="xxxr-borders shading">20 (10.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Night sweats</td><td class="xxxx-borders">3 (2.9)</td><td class="xxxx-borders">28 (26.9)<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">14 (6.8)</td><td class="xxxx-borders">5 (5)</td><td class="xxxx-borders">24 (25)<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxr-borders">20 (10.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Fatigue</td><td class="xxxx-borders shading">2 (2.0)</td><td class="xxxx-borders shading">1 (1.0)</td><td class="xxxx-borders shading">14 (6.8)</td><td class="xxxx-borders shading">5 (5)</td><td class="xxxx-borders shading">3 (3)</td><td class="xxxr-borders shading">10 (5.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Dysmenorrhea</td><td class="xxxx-borders">4 (3.9)</td><td class="xxxx-borders">1 (1.0)</td><td class="xxxx-borders">13 (6.3)</td><td class="xxxx-borders">6 (6)</td><td class="xxxx-borders">0<a href="#t3fn3" role="doc-noteref">‡</a></td><td class="xxxr-borders">7 (3.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Metrorrhagia</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (1.0)</td><td class="xxxx-borders shading">13 (6.3)<a href="#t3fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">7 (3.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Nasopharyngitis</td><td class="xxxx-borders">4 (3.9)</td><td class="xxxx-borders">6 (5.8)</td><td class="xxxx-borders">10 (4.9)</td><td class="xxxx-borders">8 (9)</td><td class="xxxx-borders">4 (4)</td><td class="xxxr-borders">10 (5.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Decreased libido</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">5 (4.8)</td><td class="xxxx-borders shading">7 (3.4)</td><td class="xxxx-borders shading">2 (2)</td><td class="xxxx-borders shading">3 (3)</td><td class="xxxr-borders shading">10 (5.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">Urinary tract infection</td><td class="xbxx-borders">3 (2.9)</td><td class="xbxx-borders">3 (2.9)</td><td class="xbxx-borders">3 (1.5)</td><td class="xbxx-borders">5 (5)</td><td class="xbxx-borders">2 (2)</td><td class="xbxr-borders">12 (6.3)</td></tr></tbody></table></div><figcaption><div class="caption">Adverse Events.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">All adverse events were summarized with the use of the <i>Medical Dictionary for Regulatory Activities</i>, version 21.0, and are listed in descending order of incidence, starting with women who received elagolix with add-back therapy, then women who received elagolix alone, and then women who received placebo in Elaris UF-1, followed by women who received elagolix with add-back therapy, then women who received elagolix alone, and then women who received placebo in Elaris UF-2.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">P&lt;0.001 for the comparison with placebo, according to Fisher’s exact test.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t3fn3" role="paragraph">P&lt;0.05 for the comparison with placebo, according to Fisher’s exact test.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t3fn4" role="paragraph">Serious adverse events were defined as life-threatening, resulting in hospitalization or medical or surgical intervention to prevent a serious outcome, or resulting in persistent disability or death.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t3fn5" role="paragraph">The severity of each adverse event was rated by the investigators as mild, moderate, or severe.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t3fn6" role="paragraph">P&lt;0.01 for the comparison with placebo, according to Fisher’s exact test.</div></div></div></figcaption></figure></div><div role="paragraph">There were no significant differences in the trials between the women who received elagolix with add-back therapy and those who received placebo with respect to the mean percent change in bone mineral density in the lumbar spine, total hip, or femoral neck from baseline to 6 months (<a href="#f2">Figure 2</a>). Although not all patients had a decrease in bone mineral density, the mean percent decrease in bone mineral density was significantly smaller with elagolix plus add-back therapy than with elagolix alone in all locations, except the femoral neck in UF-2. (Categorical assessments of changes in bone mineral density are summarized in Figure S8.)</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1904351_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1904351_f2.jpg"><img src="/cms/10.1056/NEJMoa1904351/asset/1c2251f5-8322-49c9-9064-3c78cfc70a9d/assets/images/large/nejmoa1904351_f2.jpg" height="1789" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Mean Percent Change from Baseline to 6 Months in Bone Mineral Density.</div><div class="notes"><div role="doc-footnote">At 6 months, all the differences in the percent change in bone mineral density between the group of women who received elagolix with add-back therapy and the group of women who received placebo were not significant, whereas the differences in the percent change in bone mineral density between the elagolix-alone group and the placebo group were significant, except for the between-group difference at the femoral neck in Elaris UF-2. Statistical comparisons between the trial groups were analyzed with the use of an analysis of covariance model, with treatment as the main effect and the baseline bone mineral density value as a covariate. The 𝙸 bars indicate 95% confidence intervals. LS denotes least squares.</div></div></figcaption></figure></div><div role="paragraph"><a id="exam-tint-three-d"></a><span id="tint6" class="named-content" data-type="exam-tint" data-answer-ids="three-d">Both elagolix groups had a mean increase from baseline in serum lipid levels (i.e., total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride levels), relative to placebo. These increases generally occurred within the first 3 months after initiation of treatment and then stabilized (Fig. S9).</span></div><div role="paragraph">The mean levels of liver aminotransferases, alkaline phosphatase, and bilirubin from baseline to 6 months were not significantly higher in the group of women who received elagolix plus add-back therapy than in the group of women who received placebo (Fig. S10). Across both trials, 10 women — all in the elagolix groups (6 in UF-1: 3 [2.9%] in elagolix alone and 3 [1.5%] in elagolix with add-back therapy; 4 in UF-2: 1 [1%] in elagolix alone and 3 [1.6%] in elagolix with add-back therapy) — had elevations in liver aminotransferases that were greater than 3 times the upper limit of the normal range; none of these women had concurrent elevations in bilirubin levels. All elevated aminotransferase levels returned to the normal range, with the decline seen within 1 to 4 months after peak values, regardless of whether the women continued to receive elagolix (8 women) or not (2 women).</div><div role="paragraph">Despite cycle-related differences, there was a decrease in mean endometrial thickness among women who received elagolix plus add-back therapy at 6 months (Fig. S11). <a id="exam-tint-three-c"></a><span id="tint7" class="named-content" data-type="exam-tint" data-answer-ids="three-c">No cases of endometrial hyperplasia or cancer were detected on endometrial biopsies in the elagolix groups; there was one case of hyperplasia in the placebo group (Table S9).</span> No new ovarian cysts were reported during elagolix treatment (Table S10).</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">In two identical, double-blind, randomized, placebo-controlled, 6-month phase 3 trials involving women with heavy menstrual bleeding associated with uterine fibroids, menstrual blood loss was significantly lower among women who received elagolix with add-back therapy than among those who received placebo. Elagolix with add-back therapy was associated with a significantly greater mean reduction in menstrual blood loss from baseline to the final month, a higher percentage of women with suppression of bleeding, a greater mean reduction in menstrual blood loss from baseline to 6 months and 3 months, a higher percentage of women with a low baseline hemoglobin level (≤10.5 g per deciliter) who had an increase in the hemoglobin level that was greater than 2 g per deciliter at 6 months, and a greater mean reduction in menstrual blood loss from baseline to 1 month. Findings with respect to uterine volume (measured by means of magnetic resonance imaging) and improvements in quality of life were consistent with the effects on the primary and secondary end points.</div><div role="paragraph">Elagolix was associated with a low incidence of serious adverse events; none of these events were related to drug-induced liver injury, and there were no clinically meaningful endometrial abnormalities. <a id="exam-tint-three-a"></a><span id="tint8" class="named-content" data-type="exam-tint" data-answer-ids="three-a">Elagolix with add-back therapy attenuated decreases in bone mineral density seen with elagolix alone.</span> In both trials, the mean percent changes in bone mineral density in all measured sites did not significantly differ between the groups of women who received elagolix with add-back therapy and those who received placebo. <span id="tint9" class="named-content" data-type="exam-tint" data-answer-ids="three-a">The decreases from baseline in bone mineral density that occurred in women who received elagolix alone were significantly greater than in those who received elagolix with add-back therapy and also significantly greater than in those who received placebo (except at the femoral neck in UF-2).</span> The attenuation of hypoestrogenic effects in women who received elagolix plus add-back therapy as compared with those who received elagolix alone is consistent with the results of other trials of GnRH analogues.<sup><a href="#core-r28" role="doc-biblioref" data-xml-rid="r28 r29" id="body-ref-r29-2" href-manipulated="true">28,29</a></sup> Because of the mechanism of action, hot flushes still occurred in a higher percentage of women who received elagolix with add-back therapy than in those who received placebo.</div><div role="paragraph">These large prospective trials involving women with uterine fibroids included a high percentage of black women, who are at higher risk for uterine fibroids and tend to have more severe symptoms than white women. The alkaline hematin method was used to quantify all bleeding end points.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r4 r5 r33 r34 r35 r36 r37 r38 r39" id="body-ref-r39" href-manipulated="true">3–5,33–39</a></sup> The present data inform the efficacy and safety of this treatment through 6 months; the 6-month extension trial (up to 12 months of treatment) was conducted to provide more information on longer-term benefits and risks of elagolix with add-back therapy, as was previously shown in extension studies of elagolix in women with endometriosis-associated pain.<sup><a href="#core-r40" role="doc-biblioref" data-xml-rid="r40" id="body-ref-r40" href-manipulated="true" aria-label="Reference 40">40</a></sup> Since the trials were designed primarily to compare elagolix plus add-back therapy with placebo and prespecified a comparison of the two elagolix groups only with respect to bone mineral density, we cannot make conclusions regarding elagolix with add-back therapy as compared with elagolix alone with respect to the effects on other outcomes.</div><div role="paragraph">In both trials reported here, the risk of heavy menstrual bleeding among premenopausal women with uterine fibroids was significantly lower among women who received elagolix, an oral GnRH antagonist, at a dose of 300 mg twice daily with add-back therapy for 6 months than among those who received placebo. As compared with elagolix alone, add-back therapy attenuated decreases in bone mineral density associated with elagolix alone.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">AbbVie</span>.</div><div role="paragraph">Dr. Schlaff reports receiving consulting fees from Antares Pharma and grant support and consulting fees from AbbVie; Dr. Ackerman, receiving grant support from Myovant Sciences, Watson Laboratories, and AbbVie; Dr. Al-Hendy, receiving consulting fees from AbbVie, Allergan, Bayer, Myovant Sciences, and MD Stem Cells and holding patent 9,790,562 B2 on methods for new diagnostic methods and therapeutic agents for uterine sarcoma; Dr. Archer, receiving grant support from Actavis, Glenmark Pharmaceuticals, Merck, ObsEva, Myovant Sciences, Shionogi, and AbbVie, grant support and travel support from Bayer Healthcare, and grant support, honoraria, lecture fees, and travel support from Endoceutics and TherapeuticsMD; Dr. Barnhart, receiving consulting fees from Bayer and AbbVie; Dr. Bradley, receiving grant support and advisory board fees from Bayer, advisory board fees from Medtronics and AbbVie, and fees for serving on a data and safety monitoring board from Gynesonics; Dr. Carr, receiving grant support from Synteract and AbbVie and fees for serving on a data and safety monitoring board from Repros Therapeutics; Dr. Feinberg, receiving consulting fees from AbbVie, Natera, and CooperSurgical; Dr. Hurtado, receiving grant support from Myovant Sciences, Bayer, ObsEva, Femasys, Ferring Pharmaceuticals, Allergan, Amgen, and TherapeuticsMD, grant support and fees for serving on a speakers bureau from AbbVie, and fees for serving on a speakers bureau from Merck; Dr. Kim, receiving consulting fees from AbbVie; Dr. Liu, being employed by and having an equity interest in AbbVie; Dr. Mabey, receiving grant support from AbbVie; Dr. Owens, being employed by AbbVie; Dr. Poindexter, receiving grant support from AbbVie, Bayer, Allergan, and ObsEva; Dr. Puscheck, receiving grant support from Bayer, Ferring Pharmaceuticals, and ObsEva, and fees for serving on a clinical events committee from Femasys; Dr. Rodriguez-Ginorio, serving as principal investigator for AbbVie; Dr. Simon, receiving grant support and consulting fees from Endoceutics and Palatin Technologies, grant support from Ipsen, Symbio, Viveve, and Hologic, consulting fees and nonfinancial support (editorial review and writing assistance, statistical support, or database access) from CEEK and Sprout Pharmaceuticals, consulting fees from Ascendia Pharmaceuticals, Dare Bioscience, KaNDy Therapeutics, Mitsubishi Tanabe Pharma, and Sanofi, fees for serving on a data and safety monitoring board from Covance, grant support, consulting fees, and fees for serving on a speakers bureau from Duchesnay, consulting fees, fees for serving on a speakers bureau, and nonfinancial support from Shionogi, grant support, consulting fees, fees for serving on a speakers bureau, and nonfinancial support from TherapeuticsMD and AMAG Pharmaceuticals, fees for serving on a speakers bureau from Novo Nordisk, grant support, consulting fees, and nonfinancial support from Myovant Sciences, Allergan, ObsEva, and Bayer, and consulting fees and lecture fees from AbbVie; Dr. Soliman, being employed by and owning stock in AbbVie; Dr. Stewart, receiving consulting fees from Bayer, Welltwigs, AbbVie, and Allergan, fees for serving on a steering committee from Myovant Sciences, fees for development of educational content from Med Learning Group, and holding patent 6440445 on Methods and Compounds for Treatment of Abnormal Uterine Bleeding; Dr. Watts, receiving consulting fees from AbbVie, consulting fees and lecture fees from Amgen, and lecture fees from Radius Health; and Dr. Muneyyirci-Delale, receiving grant support from Bayer, ObsEva, and Ferring Pharmaceuticals. No other potential conflict of interest relevant to this article was reported.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank all the women and the trial investigators who participated in these clinical trials; all vendors who supported the trials; and AbbVie employees, including the trial team for their operational support of these trials; Jeanie K. Meckes, Ph.D., and Amy Spiegel, Ph.D., for assistance in medical writing; Kristof Chwalisz, M.D., Ph.D., for contributions to the uterine fibroid program; James W. Thomas, M.S., for contributions to the trial design and statistical interpretation; and Yanping Luo, Ph.D., for contributions to imaging applications.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa1904351_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1904351/suppl_file/nejmoa1904351_protocol.pdf" download="nejmoa1904351_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1904351_protocol.pdf" data-doi="10.1056/NEJMoa1904351">Download</a></li><li>8.63 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa1904351_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1904351/suppl_file/nejmoa1904351_appendix.pdf" download="nejmoa1904351_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1904351_appendix.pdf" data-doi="10.1056/NEJMoa1904351">Download</a></li><li>1.16 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa1904351_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1904351/suppl_file/nejmoa1904351_disclosures.pdf" download="nejmoa1904351_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1904351_disclosures.pdf" data-doi="10.1056/NEJMoa1904351">Download</a></li><li>491.03 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa1904351_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1904351/suppl_file/nejmoa1904351_data-sharing.pdf" download="nejmoa1904351_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1904351_data-sharing.pdf" data-doi="10.1056/NEJMoa1904351">Download</a></li><li>58.46 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Bulun SE. Uterine fibroids. <em>N Engl J Med</em> 2013;369:1344-1355.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_2_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1904351&amp;key=10.1056%2FNEJMra1209993&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24088094/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000325111200012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Uterine+fibroids.&amp;publication_year=2013&amp;journal=N+Engl+J+Med&amp;pages=1344-1355&amp;doi=10.1056%2FNEJMra1209993&amp;pmid=24088094" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Moravek MB, Bulun SE. Endocrinology of uterine fibroids: steroid hormones, stem cells, and genetic contribution. <em>Curr Opin Obstet Gynecol</em> 2015;27:276-283.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/GCO.0000000000000185" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26107781/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000369598300006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Endocrinology+of+uterine+fibroids%3A+steroid+hormones%2C+stem+cells%2C+and+genetic+contribution.&amp;publication_year=2015&amp;journal=Curr+Opin+Obstet+Gynecol&amp;pages=276-283&amp;doi=10.1097%2FGCO.0000000000000185&amp;pmid=26107781" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. <em>Am J Obstet Gynecol</em> 2003;188:100-107.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1067/mob.2003.99" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12548202/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000180676900018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=High+cumulative+incidence+of+uterine+leiomyoma+in+black+and+white+women%3A+ultrasound+evidence.&amp;publication_year=2003&amp;journal=Am+J+Obstet+Gynecol&amp;pages=100-107&amp;doi=10.1067%2Fmob.2003.99&amp;pmid=12548202" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] symptomatic in up to 50% of affected women. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r39" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] used to quantify all bleeding end points. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. <em>BJOG</em> 2017;124:1501-1512.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/1471-0528.14640" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28296146/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000407971500008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Epidemiology+of+uterine+fibroids%3A+a+systematic+review.&amp;publication_year=2017&amp;journal=BJOG&amp;pages=1501-1512&amp;doi=10.1111%2F1471-0528.14640&amp;pmid=28296146" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] symptomatic in up to 50% of affected women. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r39" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] used to quantify all bleeding end points. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Stewart EA, Nicholson WK, Bradley L, Borah BJ. The burden of uterine fibroids for African-American women: results of a national survey. <em>J Womens Health (Larchmt)</em> 2013;22:807-816.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1089/jwh.2013.4334" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24033092/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000325136500005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+burden+of+uterine+fibroids+for+African-American+women%3A+results+of+a+national+survey.&amp;publication_year=2013&amp;journal=J+Womens+Health+%28Larchmt%29&amp;pages=807-816&amp;doi=10.1089%2Fjwh.2013.4334&amp;pmid=24033092" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] symptomatic in up to 50% of affected women. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r39" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] used to quantify all bleeding end points. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Stewart EA. Uterine fibroids. <em>Lancet</em> 2001;357:293-298.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(00)03622-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11214143/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000166693400035" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Uterine+fibroids.&amp;publication_year=2001&amp;journal=Lancet&amp;pages=293-298&amp;doi=10.1016%2FS0140-6736%2800%2903622-9&amp;pmid=11214143" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] bleeding, which can lead to anemia. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and complications of pregnancy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] in adverse hypoestrogenic effects. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Wegienka G, Baird DD, Hertz-Picciotto I, et al. Self-reported heavy bleeding associated with uterine leiomyomata. <em>Obstet Gynecol</em> 2003;101:431-437.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12636944/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000181360500005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Self-reported+heavy+bleeding+associated+with+uterine+leiomyomata.&amp;publication_year=2003&amp;journal=Obstet+Gynecol&amp;pages=431-437&amp;pmid=12636944" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Napolitano M, Dolce A, Celenza G, et al. Iron-dependent erythropoiesis in women with excessive menstrual blood losses and women with normal menses. <em>Ann Hematol</em> 2014;93:557-563.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00277-013-1901-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24048634/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000332712600002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Iron-dependent+erythropoiesis+in+women+with+excessive+menstrual+blood+losses+and+women+with+normal+menses.&amp;publication_year=2014&amp;journal=Ann+Hematol&amp;pages=557-563&amp;doi=10.1007%2Fs00277-013-1901-3&amp;pmid=24048634" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Zimmermann A, Bernuit D, Gerlinger C, Schaefers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. <em>BMC Womens Health</em> 2012;12:6-6.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/1472-6874-12-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22448610/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000313498500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Prevalence%2C+symptoms+and+management+of+uterine+fibroids%3A+an+international+internet-based+survey+of+21%2C746+women.&amp;publication_year=2012&amp;journal=BMC+Womens+Health&amp;pages=6-6&amp;doi=10.1186%2F1472-6874-12-6&amp;pmid=22448610" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and complications of pregnancy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] is the most common intervention. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] resonance–guided focused ultrasonography). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. <em>Fertil Steril</em> 2007;87:725-736.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.fertnstert.2007.01.093" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17430732/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000245788600003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Etiology%2C+symptomatology%2C+and+diagnosis+of+uterine+myomas.&amp;publication_year=2007&amp;journal=Fertil+Steril&amp;pages=725-736&amp;doi=10.1016%2Fj.fertnstert.2007.01.093&amp;pmid=17430732" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Stewart EA. Uterine fibroids. <em>N Engl J Med</em> 2015;372:1646-1655.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_12_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1904351&amp;key=10.1056%2FNEJMcp1411029&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25901428/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000353294000010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Uterine+fibroids.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=1646-1655&amp;doi=10.1056%2FNEJMcp1411029&amp;pmid=25901428" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and complications of pregnancy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] is the most common intervention. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Levy G, Hill MJ, Beall S, Zarek SM, Segars JH, Catherino WH. Leiomyoma: genetics, assisted reproduction, pregnancy and therapeutic advances. <em>J Assist Reprod Genet</em> 2012;29:703-712.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s10815-012-9784-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22584729/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000308184900002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Leiomyoma%3A+genetics%2C+assisted+reproduction%2C+pregnancy+and+therapeutic+advances.&amp;publication_year=2012&amp;journal=J+Assist+Reprod+Genet&amp;pages=703-712&amp;doi=10.1007%2Fs10815-012-9784-0&amp;pmid=22584729" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Fuldeore MJ, Soliman AM. Patient-reported prevalence and symptomatic burden of uterine fibroids among women in the United States: findings from a cross-sectional survey analysis. <em>Int J Womens Health</em> 2017;9:403-411.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2147/IJWH.S133212" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28652819/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000403598900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Patient-reported+prevalence+and+symptomatic+burden+of+uterine+fibroids+among+women+in+the+United+States%3A+findings+from+a+cross-sectional+survey+analysis.&amp;publication_year=2017&amp;journal=Int+J+Womens+Health&amp;pages=403-411&amp;doi=10.2147%2FIJWH.S133212&amp;pmid=28652819" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Soliman AM, Margolis MK, Castelli-Haley J, Fuldeore MJ, Owens CD, Coyne KS. Impact of uterine fibroid symptoms on health-related quality of life of US women: evidence from a cross-sectional survey. <em>Curr Med Res Opin</em> 2017;33:1971-1978.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/03007995.2017.1372107" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28836862/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000413854200009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Impact+of+uterine+fibroid+symptoms+on+health-related+quality+of+life+of+US+women%3A+evidence+from+a+cross-sectional+survey.&amp;publication_year=2017&amp;journal=Curr+Med+Res+Opin&amp;pages=1971-1978&amp;doi=10.1080%2F03007995.2017.1372107&amp;pmid=28836862" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Ghant MS, Sengoba KS, Recht H, Cameron KA, Lawson AK, Marsh EE. Beyond the physical: a qualitative assessment of the burden of symptomatic uterine fibroids on women’s emotional and psychosocial health. <em>J Psychosom Res</em> 2015;78:499-503.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jpsychores.2014.12.016" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25725565/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000352926600015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Beyond+the+physical%3A+a+qualitative+assessment+of+the+burden+of+symptomatic+uterine+fibroids+on+women%E2%80%99s+emotional+and+psychosocial+health.&amp;publication_year=2015&amp;journal=J+Psychosom+Res&amp;pages=499-503&amp;doi=10.1016%2Fj.jpsychores.2014.12.016&amp;pmid=25725565" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ, Segars JH. The estimated annual cost of uterine leiomyomata in the United States. <em>Am J Obstet Gynecol</em> 2012;206(3):211.e1-9.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ajog.2011.12.002" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22244472/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000300878600021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+estimated+annual+cost+of+uterine+leiomyomata+in+the+United+States.&amp;publication_year=2012&amp;journal=Am+J+Obstet+Gynecol&amp;pages=211.e1-9&amp;doi=10.1016%2Fj.ajog.2011.12.002&amp;pmid=22244472" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and social well-being, and overall health, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] economic burden on women and society. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Fuldeore M, Yang H, Soliman AM, Winkel C. Healthcare utilization and costs among women diagnosed with uterine fibroids: a longitudinal evaluation for 5 years pre- and post-diagnosis. <em>Curr Med Res Opin</em> 2015;31:1719-1731.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1185/03007995.2015.1069738" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26153675/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000361328000011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Healthcare+utilization+and+costs+among+women+diagnosed+with+uterine+fibroids%3A+a+longitudinal+evaluation+for+5+years+pre-+and+post-diagnosis.&amp;publication_year=2015&amp;journal=Curr+Med+Res+Opin&amp;pages=1719-1731&amp;doi=10.1185%2F03007995.2015.1069738&amp;pmid=26153675" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and social well-being, and overall health, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] economic burden on women and society. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Soliman AM, Anand SB, Coyne KS, Castelli-Haley J, Snabes M, Owens CD. Examining the relationship between symptomatic burden and self-reported productivity losses among patients with uterine fibroids in the United States. <em>J Occup Environ Med</em> 2017;59:974-981.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/JOM.0000000000001105" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28692605/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000412539800016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Examining+the+relationship+between+symptomatic+burden+and+self-reported+productivity+losses+among+patients+with+uterine+fibroids+in+the+United+States.&amp;publication_year=2017&amp;journal=J+Occup+Environ+Med&amp;pages=974-981&amp;doi=10.1097%2FJOM.0000000000001105&amp;pmid=28692605" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and social well-being, and overall health, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] economic burden on women and society. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Yao X, Stewart EA, Laughlin-Tommaso SK, Heien HC, Borah BJ. Medical therapies for heavy menstrual bleeding in women with uterine fibroids: a retrospective analysis of a large commercially insured population in the USA. <em>BJOG</em> 2017;124:322-330.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/1471-0528.14383" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27770484/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000396378500028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Medical+therapies+for+heavy+menstrual+bleeding+in+women+with+uterine+fibroids%3A+a+retrospective+analysis+of+a+large+commercially+insured+population+in+the+USA.&amp;publication_year=2017&amp;journal=BJOG&amp;pages=322-330&amp;doi=10.1111%2F1471-0528.14383&amp;pmid=27770484" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. <em>Obstet Gynecol</em> 2010;116:865-875.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/AOG.0b013e3181f20177" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20859150/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000282067700011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Tranexamic+acid+treatment+for+heavy+menstrual+bleeding%3A+a+randomized+controlled+trial.&amp;publication_year=2010&amp;journal=Obstet+Gynecol&amp;pages=865-875&amp;doi=10.1097%2FAOG.0b013e3181f20177&amp;pmid=20859150" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Borah BJ, Yao X, Laughlin-Tommaso SK, Heien HC, Stewart EA. Comparative effectiveness of uterine leiomyoma procedures using a large insurance claims database. <em>Obstet Gynecol</em> 2017;130:1047-1056.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/AOG.0000000000002331" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29016510/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000417651200029" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparative+effectiveness+of+uterine+leiomyoma+procedures+using+a+large+insurance+claims+database.&amp;publication_year=2017&amp;journal=Obstet+Gynecol&amp;pages=1047-1056&amp;doi=10.1097%2FAOG.0000000000002331&amp;pmid=29016510" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Gurusamy KS, Vaughan J, Fraser IS, Best LM, Richards T. Medical therapies for uterine fibroids — a systematic review and network meta-analysis of randomised controlled trials. <em>PLoS One</em> 2016;11(2):e0149631-e0149631.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r22" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0149631" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26919185/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000371274400030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Medical+therapies+for+uterine+fibroids+%E2%80%94+a+systematic+review+and+network+meta-analysis+of+randomised+controlled+trials.&amp;publication_year=2016&amp;journal=PLoS+One&amp;pages=e0149631-e0149631&amp;doi=10.1371%2Fjournal.pone.0149631&amp;pmid=26919185" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r22" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r22-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with symptomatic fibroids are limited. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in adverse hypoestrogenic effects. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. <em>Hum Reprod Update</em> 2016;22:665-686.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/humupd/dmw023" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27466209/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000388934600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Uterine+fibroid+management%3A+from+the+present+to+the+future.&amp;publication_year=2016&amp;journal=Hum+Reprod+Update&amp;pages=665-686&amp;doi=10.1093%2Fhumupd%2Fdmw023&amp;pmid=27466209" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Carr BR, Marshburn PB, Weatherall PT, et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. <em>J Clin Endocrinol Metab</em> 1993;76:1217-1223.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1210/jc.76.5.1217" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/8496313/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1993LD04500023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=An+evaluation+of+the+effect+of+gonadotropin-releasing+hormone+analogs+and+medroxyprogesterone+acetate+on+uterine+leiomyomata+volume+by+magnetic+resonance+imaging%3A+a+prospective%2C+randomized%2C+double+blind%2C+placebo-controlled%2C+crossover+trial.&amp;publication_year=1993&amp;journal=J+Clin+Endocrinol+Metab&amp;pages=1217-1223&amp;doi=10.1210%2Fjc.76.5.1217&amp;pmid=8496313" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Ng J, Chwalisz K, Carter DC, Klein CE. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. <em>J Clin Endocrinol Metab</em> 2017;102:1683-1691.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r25" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1210/jc.2016-3845" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28323948/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000402614700030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dose-dependent+suppression+of+gonadotropins+and+ovarian+hormones+by+elagolix+in+healthy+premenopausal+women.&amp;publication_year=2017&amp;journal=J+Clin+Endocrinol+Metab&amp;pages=1683-1691&amp;doi=10.1210%2Fjc.2016-3845&amp;pmid=28323948" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r25" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r27-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and ovarian sex hormones in women. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r25-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of the drug, owing to its short half-life. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. <em>J Clin Endocrinol Metab</em> 2009;94:545-551.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1210/jc.2008-1695" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19033369/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000263072700033" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Suppression+of+gonadotropins+and+estradiol+in+premenopausal+women+by+oral+administration+of+the+nonpeptide+gonadotropin-releasing+hormone+antagonist+elagolix.&amp;publication_year=2009&amp;journal=J+Clin+Endocrinol+Metab&amp;pages=545-551&amp;doi=10.1210%2Fjc.2008-1695&amp;pmid=19033369" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. <em>N Engl J Med</em> 2017;377:28-40.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r27" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_28_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1904351&amp;key=10.1056%2FNEJMoa1700089&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28525302/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000404730000006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+of+endometriosis-associated+pain+with+elagolix%2C+an+oral+GnRH+antagonist.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=28-40&amp;doi=10.1056%2FNEJMoa1700089&amp;pmid=28525302" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r27" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r27-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and ovarian sex hormones in women. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] consistent with its mechanism of action. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Friedman AJ, Daly M, Juneau-Norcross M, Gleason R, Rein MS, LeBoff M. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin ‘add-back’ for 2 years. <em>Hum Reprod</em> 1994;9:1618-1625.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r28" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/oxfordjournals.humrep.a138762" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/7836510/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1994PK04600007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+medical+therapy+for+leiomyomata+uteri%3A+a+prospective%2C+randomized+study+of+leuprolide+acetate+depot+plus+either+oestrogen-progestin+or+progestin+%E2%80%98add-back%E2%80%99+for+2+years.&amp;publication_year=1994&amp;journal=Hum+Reprod&amp;pages=1618-1625&amp;doi=10.1093%2Foxfordjournals.humrep.a138762&amp;pmid=7836510" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r28" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r29-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] effects, as observed in other studies. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r29-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] results of other trials of GnRH analogues. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Hornstein MD, Surrey ES, Weisberg GW, Casino LA. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. <em>Obstet Gynecol</em> 1998;91:16-24.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r29" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0029-7844(97)00620-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/9464714/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000071237300004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Leuprolide+acetate+depot+and+hormonal+add-back+in+endometriosis%3A+a+12-month+study.&amp;publication_year=1998&amp;journal=Obstet+Gynecol&amp;pages=16-24&amp;doi=10.1016%2FS0029-7844%2897%2900620-0&amp;pmid=9464714" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r29" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r29-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] effects, as observed in other studies. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r29-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] results of other trials of GnRH analogues. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">Magnay JL, Schönicke G, Nevatte TM, O’Brien S, Junge W. Validation of a rapid alkaline hematin technique to measure menstrual blood loss on feminine towels containing superabsorbent polymers. <em>Fertil Steril</em> 2011;96:394-398.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.fertnstert.2011.05.096" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21719001/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000293008700053" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Validation+of+a+rapid+alkaline+hematin+technique+to+measure+menstrual+blood+loss+on+feminine+towels+containing+superabsorbent+polymers.&amp;publication_year=2011&amp;journal=Fertil+Steril&amp;pages=394-398&amp;doi=10.1016%2Fj.fertnstert.2011.05.096&amp;pmid=21719001" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="r31" class="citations"><div class="citation"><div class="citation-content">Coyne KS, Soliman AM, Margolis MK, Thompson CL, Chwalisz K. Validation of the 4 week recall version of the Uterine Fibroid Symptom and Health-related Quality of Life (UFS-QOL) Questionnaire. <em>Curr Med Res Opin</em> 2017;33:193-200.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/03007995.2016.1248382" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27733082/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000392670300004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Validation+of+the+4+week+recall+version+of+the+Uterine+Fibroid+Symptom+and+Health-related+Quality+of+Life+%28UFS-QOL%29+Questionnaire.&amp;publication_year=2017&amp;journal=Curr+Med+Res+Opin&amp;pages=193-200&amp;doi=10.1080%2F03007995.2016.1248382&amp;pmid=27733082" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="r32" class="citations"><div class="citation"><div class="citation-content">Carr BR, Stewart EA, Archer DF, et al. Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and uterine leiomyomas: a randomized controlled trial. <em>Obstet Gynecol</em> 2018;132:1252-1264.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/AOG.0000000000002933" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30303923/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000454042600027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Elagolix+alone+or+with+add-back+therapy+in+women+with+heavy+menstrual+bleeding+and+uterine+leiomyomas%3A+a+randomized+controlled+trial.&amp;publication_year=2018&amp;journal=Obstet+Gynecol&amp;pages=1252-1264&amp;doi=10.1097%2FAOG.0000000000002933&amp;pmid=30303923" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="r33" class="citations"><div class="citation"><div class="citation-content">Higham JM, O’Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. <em>Br J Obstet Gynaecol</em> 1990;97:734-739.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1471-0528.1990.tb16249.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/2400752/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1990DU88800016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Assessment+of+menstrual+blood+loss+using+a+pictorial+chart.&amp;publication_year=1990&amp;journal=Br+J+Obstet+Gynaecol&amp;pages=734-739&amp;doi=10.1111%2Fj.1471-0528.1990.tb16249.x&amp;pmid=2400752" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="r34" class="citations"><div class="citation"><div class="citation-content">Mansfield PK, Voda A, Allison G. Validating a pencil-and-paper measure of perimenopausal menstrual blood loss. <em>Womens Health Issues</em> 2004;14:242-247.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.whi.2004.07.005" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15589775/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000225892000011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Validating+a+pencil-and-paper+measure+of+perimenopausal+menstrual+blood+loss.&amp;publication_year=2004&amp;journal=Womens+Health+Issues&amp;pages=242-247&amp;doi=10.1016%2Fj.whi.2004.07.005&amp;pmid=15589775" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="r35" class="citations"><div class="citation"><div class="citation-content">Reid PC, Coker A, Coltart R. Assessment of menstrual blood loss using a pictorial chart: a validation study. <em>BJOG</em> 2000;107:320-322.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1471-0528.2000.tb13225.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/10740326/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000086077300007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Assessment+of+menstrual+blood+loss+using+a+pictorial+chart%3A+a+validation+study.&amp;publication_year=2000&amp;journal=BJOG&amp;pages=320-322&amp;doi=10.1111%2Fj.1471-0528.2000.tb13225.x&amp;pmid=10740326" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="r36" class="citations"><div class="citation"><div class="citation-content">Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. <em>N Engl J Med</em> 2012;366:409-420.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_37_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1904351&amp;key=10.1056%2FNEJMoa1103182&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22296075/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000299724400006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ulipristal+acetate+versus+placebo+for+fibroid+treatment+before+surgery.&amp;publication_year=2012&amp;journal=N+Engl+J+Med&amp;pages=409-420&amp;doi=10.1056%2FNEJMoa1103182&amp;pmid=22296075" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">37.</div><div id="r37" class="citations"><div class="citation"><div class="citation-content">Simon JA, Catherino W, Segars JH, et al. Ulipristal acetate for treatment of symptomatic uterine leiomyomas: a randomized controlled trial. <em>Obstet Gynecol</em> 2018;131:431-439.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/AOG.0000000000002462" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29420395/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000428994700007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ulipristal+acetate+for+treatment+of+symptomatic+uterine+leiomyomas%3A+a+randomized+controlled+trial.&amp;publication_year=2018&amp;journal=Obstet+Gynecol&amp;pages=431-439&amp;doi=10.1097%2FAOG.0000000000002462&amp;pmid=29420395" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">38.</div><div id="r38" class="citations"><div class="citation"><div class="citation-content">Seitz C, Bumbuliene Ž, Costa AR, et al. Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids. <em>Contemp Clin Trials</em> 2017;55:56-62.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cct.2017.02.002" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28185997/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000397692100008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rationale+and+design+of+ASTEROID+2%2C+a+randomized%2C+placebo-+and+active+comparator-controlled+study+to+assess+the+efficacy+and+safety+of+vilaprisan+in+patients+with+uterine+fibroids.&amp;publication_year=2017&amp;journal=Contemp+Clin+Trials&amp;pages=56-62&amp;doi=10.1016%2Fj.cct.2017.02.002&amp;pmid=28185997" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">39.</div><div id="r39" class="citations"><div class="citation"><div class="citation-content">Melis GB, Neri M, Piras B, et al. Vilaprisan for treating uterine fibroids. <em>Expert Opin Investig Drugs</em> 2018;27:497-505.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/13543784.2018.1471134" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29718788/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000432689500007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Vilaprisan+for+treating+uterine+fibroids.&amp;publication_year=2018&amp;journal=Expert+Opin+Investig+Drugs&amp;pages=497-505&amp;doi=10.1080%2F13543784.2018.1471134&amp;pmid=29718788" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">40.</div><div id="r40" class="citations"><div class="citation"><div class="citation-content">Surrey E, Taylor HS, Giudice L, et al. Long-term outcomes of elagolix in women with endometriosis: results from two extension studies. <em>Obstet Gynecol</em> 2018;132:147-160.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r40"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/AOG.0000000000002675" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29889764/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000454043200047" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+outcomes+of+elagolix+in+women+with+endometriosis%3A+results+from+two+extension+studies.&amp;publication_year=2018&amp;journal=Obstet+Gynecol&amp;pages=147-160&amp;doi=10.1097%2FAOG.0000000000002675&amp;pmid=29889764" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/382/4"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">382</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">4</span></span> • <span property="datePublished">January 23, 2020</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">328</span>-<span property="pageEnd">340</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2020 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa1904351" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYoa1904351?sg=AbW1N">Chinese Translation 中文翻译</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: January 22, 2020</div><div><b class="core-label">Published in issue</b>: January 23, 2020</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/clinical-medicine-general" alt="View article keyword Clinical Medicine General" data-interactiontype="article_recirculation_click">Clinical Medicine General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/obstetrics-gynecology-general" alt="View article keyword Obstetrics/Gynecology General" data-interactiontype="article_recirculation_click">Obstetrics/Gynecology General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">William D.</span> <span property="familyName">Schlaff</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ronald T.</span> <span property="familyName">Ackerman</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ayman</span> <span property="familyName">Al-Hendy</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">David F.</span> <span property="familyName">Archer</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kurt T.</span> <span property="familyName">Barnhart</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Linda D.</span> <span property="familyName">Bradley</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Bruce R.</span> <span property="familyName">Carr</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Eve C.</span> <span property="familyName">Feinberg</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sandra M.</span> <span property="familyName">Hurtado</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">JinHee</span> <span property="familyName">Kim</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ran</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">R. Garn</span> <span property="familyName">Mabey</span>, Jr., <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Charlotte D.</span> <span property="familyName">Owens</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Alfred</span> <span property="familyName">Poindexter</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Elizabeth E.</span> <span property="familyName">Puscheck</span>, <span property="honorificSuffix">M.D., M.B.A.</span></span>, <span property="author" typeof="Person"><span property="givenName">Henry</span> <span property="familyName">Rodriguez-Ginorio</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">James A.</span> <span property="familyName">Simon</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ahmed M.</span> <span property="familyName">Soliman</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Elizabeth A.</span> <span property="familyName">Stewart</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Nelson B.</span> <span property="familyName">Watts</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-0719-9801" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-0719-9801</a></span>, and <span property="author" typeof="Person"><span property="givenName">Ozgul</span> <span property="familyName">Muneyyirci-Delale</span>, <span property="honorificSuffix">M.D.</span></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From Thomas Jefferson University (W.D.S.) and the University of Pennsylvania (K.T.B.), Philadelphia; Comprehensive Clinical Trials, West Palm Beach, FL (R.T.A.); University of Illinois at Chicago (A.A.-H.) and Northwestern University (E.C.F.), Chicago, AbbVie, North Chicago (R.L., C.D.O., A.M.S.), and InVia Fertility, Hoffman Estates (E.E.P.) — all in Illinois; Eastern Virginia Medical School, Norfolk (D.F.A.); Cleveland Clinic, Cleveland (L.D.B.); University of Texas Southwestern Medical Center, Dallas (B.R.C.); University of Texas Health Science Center at Houston (S.M.H.) and Advances in Health (A.P.), Houston; Columbia University (J.K.) and SUNY Downstate Health Sciences University (O.M.-D.), New York; private practice, Las Vegas (R.G.M.); Wayne State University, Detroit (E.E.P.); Torre de Auxilio Mutuo, San Juan, Puerto Rico (H.R.-G.); George Washington University, Washington, DC (J.A.S.); Mayo Clinic and Mayo Clinic Alix School of Medicine, Rochester, MN (E.A.S.); and Mercy Health, Cincinnati (N.B.W.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Schlaff at Thomas Jefferson University, 833 Chestnut St., Mezzanine, Philadelphia, PA 19107, or at <a href="mailto:william.schlaff@jefferson.edu">william.schlaff@jefferson.edu</a>.</div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">154</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa1904351" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="810bf5d0-1f26-9f83-fe5e-ed06e78c473e"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=74373008" style="display:inline-block;">
                <img alt="Article has an altmetric score of 240" src="https://badges.altmetric.com/?size=320&amp;score=240&amp;types=mbcttttf" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=74373008">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_810bf5d0-1f26-9f83-fe5e-ed06e78c473e" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=74373008&amp;tab=news">
          Picked up by <b>26</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=74373008&amp;tab=blogs">
          Blogged by <b>2</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=74373008&amp;tab=twitter">
          Posted by <b>63</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=74373008&amp;tab=facebook">
          On <b>3</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=74373008&amp;tab=guidelines">
          Referenced in <b>2</b> clinical guideline sources
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>199</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d611ad83dbaf32-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa1904351"> <input type="hidden" name="downloadFileName" value="csp_382_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa1904351%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.382.issue-4%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="154" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Sven Becker, </li><li class="list-inline-item cited-by__entry__author">Marie‐Madeleine Dolmans, </li><li class="list-inline-item cited-by__entry__author">Francisco Carmona Herrera, </li><li class="list-inline-item cited-by__entry__author">Felice Petraglia, </li><li class="list-inline-item cited-by__entry__author">Stefan P. Renner, </li><li class="list-inline-item cited-by__entry__author">Raluca Ionescu‐Ittu, </li><li class="list-inline-item cited-by__entry__author">Julien St‐Pierre, </li><li class="list-inline-item cited-by__entry__author">Mitra Boolell, </li><li class="list-inline-item cited-by__entry__author">Elke Bestel, </li><li class="list-inline-item cited-by__entry__author">Satoshi Hori, </li><li class="list-inline-item cited-by__entry__author">Jacques Donnez, </li></ul><span class="cited-by__entry__title">
              Pain Reduction in Linzagolix‐Treated Patients With Uterine Fibroids: A Secondary Mediation Analysis of the
              PRIMROSE
              1 and 2 Phase 3 Trials
            , </span><span class="cited-by__entry__series-title">BJOG: An International Journal of Obstetrics &amp; Gynaecology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1111/1471-0528.18190" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1111/1471-0528.18190</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1111/1471-0528.18190" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Kelsey Musselman, </li><li class="list-inline-item cited-by__entry__author">A’Jah Chandler, </li><li class="list-inline-item cited-by__entry__author">Maria Victoria Vargas, </li></ul><span class="cited-by__entry__title">Laparoscopic and Robot-assisted Myomectomy: Optimization and Setup for Success, </span><span class="cited-by__entry__series-title">Current Obstetrics and Gynecology Reports, </span><span class="cited-by__entry__volume"><strong>14</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s13669-025-00416-2" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s13669-025-00416-2</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s13669-025-00416-2" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Marta Barretta, </li><li class="list-inline-item cited-by__entry__author">Michele Vignali, </li><li class="list-inline-item cited-by__entry__author">Antonio La Marca, </li><li class="list-inline-item cited-by__entry__author">Giovanni Grandi, </li></ul><span class="cited-by__entry__title">The oral GnRH antagonists, a new class of drugs in gynecology: from pharmacokinetics to possible clinical applications, </span><span class="cited-by__entry__series-title">Expert Opinion on Drug Metabolism &amp; Toxicology, </span><span class="cited-by__entry__volume"><strong>21</strong>, </span><span class="cited-by__entry__issue">3, </span><span class="cited-by__entry__page-range">(265-277), </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1080/17425255.2024.2441981" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1080/17425255.2024.2441981</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1080/17425255.2024.2441981" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Charles E. Miller, </li><li class="list-inline-item cited-by__entry__author">Jin Hee Kim, </li><li class="list-inline-item cited-by__entry__author">Robin Kroll, </li><li class="list-inline-item cited-by__entry__author">James A. Simon, </li><li class="list-inline-item cited-by__entry__author">Ahmed M. Soliman, </li><li class="list-inline-item cited-by__entry__author">James W. Thomas, </li><li class="list-inline-item cited-by__entry__author">Yanqing Xu, </li><li class="list-inline-item cited-by__entry__author">Juki Ng, </li><li class="list-inline-item cited-by__entry__author">Michael C. Snabes, </li></ul><span class="cited-by__entry__title">Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial, </span><span class="cited-by__entry__series-title">American Journal of Obstetrics and Gynecology, </span><span class="cited-by__entry__volume"><strong>231</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(630.e1-630.e13), </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1016/j.ajog.2024.06.040" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ajog.2024.06.040</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ajog.2024.06.040" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Elizabeth A. Stewart, </li><li class="list-inline-item cited-by__entry__author">Shannon K. Laughlin-Tommaso, </li></ul><span class="cited-by__entry__title">Uterine Fibroids, </span><span class="cited-by__entry__series-title">New England Journal of Medicine, </span><span class="cited-by__entry__volume"><strong>391</strong>, </span><span class="cited-by__entry__issue">18, </span><span class="cited-by__entry__page-range">(1721-1733), </span><span class="cited-by__entry__pub-date">(2024).</span><a href="/doi/full/10.1056/NEJMcp2309623" title="Abstract" target="_self" class="cited-by__entry__doi">/doi/full/10.1056/NEJMcp2309623</a><div class="cited-by__entry__extra-links"><a href="/doi/full/10.1056/NEJMcp2309623" target="_self" class="cited-by__entry__visitable">Abstract</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Min Mao, </li><li class="list-inline-item cited-by__entry__author">Yuanqin Gou, </li><li class="list-inline-item cited-by__entry__author">Zhigui Luo, </li><li class="list-inline-item cited-by__entry__author">Yuanhong Li, </li><li class="list-inline-item cited-by__entry__author">Yu Tong, </li></ul><span class="cited-by__entry__title">The suture fixation of the levonorgestrel-releasing intrauterine device with hysteroscope for the treatment of adenomyosis in patients at high risk of device expulsion-a prospective observational&nbsp;study, </span><span class="cited-by__entry__series-title">BMC Women's Health, </span><span class="cited-by__entry__volume"><strong>24</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1186/s12905-024-03390-8" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1186/s12905-024-03390-8</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1186/s12905-024-03390-8" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ludovico Muzii, </li><li class="list-inline-item cited-by__entry__author">Giulia Galati, </li><li class="list-inline-item cited-by__entry__author">Antonella Mercurio, </li><li class="list-inline-item cited-by__entry__author">Carlotta Olivieri, </li><li class="list-inline-item cited-by__entry__author">Letizia Scarcella, </li><li class="list-inline-item cited-by__entry__author">Ilham Azenkoud, </li><li class="list-inline-item cited-by__entry__author">Rossana Tripodi, </li><li class="list-inline-item cited-by__entry__author">Michele Vignali, </li><li class="list-inline-item cited-by__entry__author">Stefano Angioni, </li><li class="list-inline-item cited-by__entry__author">Antonio Maiorana, </li></ul><span class="cited-by__entry__title">Presurgical treatment of uterine myomas with the GnRH-antagonist relugolix in combination therapy: an observational study, </span><span class="cited-by__entry__series-title">Scientific Reports, </span><span class="cited-by__entry__volume"><strong>14</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1038/s41598-024-73151-y" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s41598-024-73151-y</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s41598-024-73151-y" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">James A. Simon, </li><li class="list-inline-item cited-by__entry__author">Elizabeth A. Stewart, </li><li class="list-inline-item cited-by__entry__author">Susan Jewell, </li><li class="list-inline-item cited-by__entry__author">Moming Li, </li><li class="list-inline-item cited-by__entry__author">Michael C. Snabes, </li></ul><span class="cited-by__entry__title">Impact of demographic and clinical factors on elagolix plus add-back therapy effects on patient-reported nonbleeding symptoms in women with heavy menstrual bleeding and uterine fibroids: a post hoc analysis of data from two clinical trials, </span><span class="cited-by__entry__series-title">F&amp;S Reports, </span><span class="cited-by__entry__volume"><strong>5</strong>, </span><span class="cited-by__entry__issue">3, </span><span class="cited-by__entry__page-range">(285-295), </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1016/j.xfre.2024.06.002" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.xfre.2024.06.002</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.xfre.2024.06.002" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Eduard Mension, </li><li class="list-inline-item cited-by__entry__author">Joaquim Calaf, </li><li class="list-inline-item cited-by__entry__author">Charles Chapron, </li><li class="list-inline-item cited-by__entry__author">Marie Madeleine Dolmans, </li><li class="list-inline-item cited-by__entry__author">Jacques Donnez, </li><li class="list-inline-item cited-by__entry__author">Louis Marcellin, </li><li class="list-inline-item cited-by__entry__author">Felice Petraglia, </li><li class="list-inline-item cited-by__entry__author">Silvia Vannuccini, </li><li class="list-inline-item cited-by__entry__author">Francisco Carmona, </li></ul><span class="cited-by__entry__title">An update on the management of uterine fibroids: personalized medicine or guidelines?, </span><span class="cited-by__entry__series-title">Journal of Endometriosis and Uterine Disorders, </span><span class="cited-by__entry__volume"><strong>7</strong>, </span><span class="cited-by__entry__page-range">(100080), </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1016/j.jeud.2024.100080" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jeud.2024.100080</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jeud.2024.100080" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">John Lugata, </li><li class="list-inline-item cited-by__entry__author">Baraka Shao, </li><li class="list-inline-item cited-by__entry__author">Laetitia Makower, </li><li class="list-inline-item cited-by__entry__author">Ashley Rapheal, </li><li class="list-inline-item cited-by__entry__author">Alex Mremi, </li><li class="list-inline-item cited-by__entry__author">Bariki Mchome, </li></ul><span class="cited-by__entry__title">Management of a large uterine fibroid arising from the cervical stump following subtotal hysterectomy causing massive abdominal distension. A rare case report and review of the current literature, </span><span class="cited-by__entry__series-title">International Journal of Surgery Case Reports, </span><span class="cited-by__entry__volume"><strong>122</strong>, </span><span class="cited-by__entry__page-range">(110160), </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1016/j.ijscr.2024.110160" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ijscr.2024.110160</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ijscr.2024.110160" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa1904351%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.382.issue-4%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa1904351" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa1904351" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1904351.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1904351_f1.jpg"><img src="/cms/10.1056/NEJMoa1904351/asset/2b6cce23-d938-4741-a88a-3b75de357388/assets/images/large/nejmoa1904351_f1.jpg" height="1514" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Reduction in Heavy Menstrual Bleeding in Women with Uterine Fibroids.</div><div class="notes"><div role="doc-footnote">Shown are the percentages of women who met the criteria for the primary end point (a menstrual blood loss [MBL] volume of &lt;80 ml in the final month and a ≥50% reduction in MBL volume from baseline to the final month) in the two trials. A significantly greater percentage of women who received elagolix with add-back therapy met the criteria for the primary end point than women who received placebo. The final month was defined as the last 28 days before and including the last treatment period visit date (if data on menstrual blood loss [measured with the use of the alkaline hematin method] that could be evaluated were available between the last treatment period visit date and the last dose date, then the last dose date was used). CI denotes confidence interval.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1904351_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1904351_f2.jpg"><img src="/cms/10.1056/NEJMoa1904351/asset/1c2251f5-8322-49c9-9064-3c78cfc70a9d/assets/images/large/nejmoa1904351_f2.jpg" height="1789" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Mean Percent Change from Baseline to 6 Months in Bone Mineral Density.</div><div class="notes"><div role="doc-footnote">At 6 months, all the differences in the percent change in bone mineral density between the group of women who received elagolix with add-back therapy and the group of women who received placebo were not significant, whereas the differences in the percent change in bone mineral density between the elagolix-alone group and the placebo group were significant, except for the between-group difference at the femoral neck in Elaris UF-2. Statistical comparisons between the trial groups were analyzed with the use of an analysis of covariance model, with treatment as the main effect and the baseline bone mineral density value as a covariate. The 𝙸 bars indicate 95% confidence intervals. LS denotes least squares.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1904351_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1904351_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1904351/asset/5ebf2fc3-378a-4473-80db-3133143aefa2/assets/images/large/nejmoa1904351_t1.jpg" height="1869" width="1435" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="3"><span>Elaris UF-1</span></th><th class="txxr-borders" colspan="3"><span>Elaris UF-2</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Placebo<br> (N=102)</th><th class="xxxx-borders">Elagolix Alone<br> (N=104)</th><th class="xxxx-borders">Elagolix with<br> Add-Back<br> Therapy<br> (N=206)</th><th class="xxxx-borders">Placebo<br> (N=94)</th><th class="xxxx-borders">Elagolix Alone<br>(N=95)</th><th class="xxxr-borders">Elagolix with<br> Add-Back<br> Therapy<br> (N=189)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Age — yr</td><td class="xxxx-borders shading">41.6±5.7</td><td class="xxxx-borders shading">42.6±5.2</td><td class="xxxx-borders shading">42.6±5.3</td><td class="xxxx-borders shading">42.5±5.4</td><td class="xxxx-borders shading">42.2±5.4</td><td class="xxxr-borders shading">42.5±5.3</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Race — no./total no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">70/102 (68.6)</td><td class="xxxx-borders shading">69/103 (67.0)</td><td class="xxxx-borders shading">141/206 (68.4)</td><td class="xxxx-borders shading">63/94 (67)</td><td class="xxxx-borders shading">66/95 (69)</td><td class="xxxr-borders shading">124/188 (66.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">30/102 (29.4)</td><td class="xxxx-borders">27/103 (26.2)</td><td class="xxxx-borders">59/206 (28.6)</td><td class="xxxx-borders">30/94 (32)</td><td class="xxxx-borders">27/95 (28)</td><td class="xxxr-borders">59/188 (31.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Other</td><td class="xxxx-borders shading">2/102 (2.0)</td><td class="xxxx-borders shading">7/103 (6.8)</td><td class="xxxx-borders shading">6/206 (3.0)</td><td class="xxxx-borders shading">1/94 (1)</td><td class="xxxx-borders shading">2/95 (2)</td><td class="xxxr-borders shading">5/188 (2.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Missing data</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Body-mass index<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">33.8±7.7</td><td class="xxxx-borders shading">33.4±7.7</td><td class="xxxx-borders shading">33.3±6.8<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">33.8±7.2</td><td class="xxxx-borders shading">34.5±7.9</td><td class="xxxr-borders shading">33.2±6.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Menstrual blood loss/menstrual cycle — ml</td><td class="xxxx-borders">255.3±174.0</td><td class="xxxx-borders">248.9±169.6</td><td class="xxxx-borders">238.0±150.1</td><td class="xxxx-borders">254.3±178.5</td><td class="xxxx-borders">224.9±146.2</td><td class="xxxr-borders">228.5±148.8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Hemoglobin level — g/dl</td><td class="xxxx-borders shading">11.0±1.4</td><td class="xxxx-borders shading">10.6±1.5</td><td class="xxxx-borders shading">11.1±1.5</td><td class="xxxx-borders shading">11.0±1.6</td><td class="xxxx-borders shading">11.0±1.6</td><td class="xxxr-borders shading">11.1±1.5</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Uterine volume — cm<sup>3</sup></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Measured with TAU or TVU</td><td class="xxxx-borders shading">478.1±356.9</td><td class="xxxx-borders shading">499.6±437.9</td><td class="xxxx-borders shading">474.9±388.2</td><td class="xxxx-borders shading">549.6± 452.1</td><td class="xxxx-borders shading">537.3±521.9</td><td class="xxxr-borders shading">496.1±381.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Measured with MRI<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">561.9±437.2</td><td class="xxxx-borders">617.0±582.3</td><td class="xxxx-borders">508.6±342.2</td><td class="xxxx-borders">798.6±730.9</td><td class="xxxx-borders">675.7±906.2</td><td class="xxxr-borders">676.8±559.1</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Average fibroid volume — cm<sup>3</sup></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Measured with TAU or TVU<a href="#core-t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">52.1±72.2</td><td class="xxxx-borders">44.2±64.2</td><td class="xxxx-borders">52.0±69.7</td><td class="xxxx-borders">73.3±100.4</td><td class="xxxx-borders">67.4±132.3</td><td class="xxxr-borders">57.3±104.8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Measured with MRI<a href="#core-t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">73.1±98.1</td><td class="xxxx-borders shading">60.2±70.3</td><td class="xxxx-borders shading">66.0±73.7</td><td class="xxxx-borders shading">104.3±120.5</td><td class="xxxx-borders shading">83.3±130.8</td><td class="xxxr-borders shading">72.0±68.2</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">UFS-QOL score<a href="#core-t1fn8" role="doc-noteref">††</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Symptom severity score<a href="#core-t1fn9" role="doc-noteref">‡‡</a></td><td class="xxxx-borders shading">61.7±19.2</td><td class="xxxx-borders shading">60.4±22.5</td><td class="xxxx-borders shading">57.3±22.2</td><td class="xxxx-borders shading">60.5±23.4</td><td class="xxxx-borders shading">63.7±20.4</td><td class="xxxr-borders shading">60.9±21.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Health-related quality-of-life total score<a href="#core-t1fn10" role="doc-noteref">§§</a></td><td class="xxxx-borders">40.7±20.3</td><td class="xxxx-borders">42.5±23.3</td><td class="xxxx-borders">44.1±23.5</td><td class="xxxx-borders">43.0±22.8</td><td class="xxxx-borders">42.2±24.0</td><td class="xxxr-borders">43.3±24.2</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Bone mineral density z score</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Lumbar spine</td><td class="xxxx-borders">0.9±1.0</td><td class="xxxx-borders">1.1±1.2</td><td class="xxxx-borders">1.0±1.0<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">1.1±1.1</td><td class="xxxx-borders">0.9±1.2</td><td class="xxxr-borders">1.1±1.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Total hip</td><td class="xxxx-borders shading">0.7±0.9</td><td class="xxxx-borders shading">0.8±0.9</td><td class="xxxx-borders shading">0.8±0.9<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">0.7±1.0</td><td class="xxxx-borders shading">0.8±1.0</td><td class="xxxr-borders shading">0.8±0.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Femoral neck</td><td class="xbxx-borders">0.5±0.8</td><td class="xbxx-borders">0.6±0.9</td><td class="xbxx-borders">0.6±0.9<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xbxx-borders">0.6±0.9</td><td class="xbxx-borders">0.6±0.9</td><td class="xbxr-borders">0.6±0.9</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD. MRI denotes magnetic resonance imaging, TAU transabdominal ultrasonography, and TVU transvaginal ultrasonography.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Race was reported by the women.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">Data shown are for 205 patients.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">For the Elaris UF-1 trial, data shown are for 48 patients who received placebo, 51 patients who received elagolix alone, and 96 patients who received elagolix with add-back therapy. For the Elaris UF-2 trial, data shown are for 51 patients who received placebo, 52 patients who received elagolix alone, and 89 patients who received elagolix with add-back therapy.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">For the Elaris UF-1 trial, data shown are for 100 patients who received placebo, 102 patients who received elagolix alone, and 203 patients who received elagolix with add-back therapy. For the Elaris UF-2 trial, data shown are for 92 patients who received placebo, 95 patients who received elagolix alone, and 186 patients who received elagolix with add-back therapy.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t1fn7" role="paragraph" data-to-manipulate="true">For the Elaris UF-1 trial, data shown are for 47 patients who received placebo, 45 patients who received elagolix alone, and 83 patients who received elagolix with add-back therapy. For the Elaris UF-2 trial, data shown are for 45 patients who received placebo, 52 patients who received elagolix alone, and 92 patients who received elagolix with add-back therapy.</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="core-t1fn8" role="paragraph" data-to-manipulate="true">On the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire, scores for symptom severity range from 0 to 100, with higher scores indicating increased severity. Total scores for health-related quality of life range from 0 to 100, with higher scores indicating a better quality of life.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡‡</div><div id="core-t1fn9" role="paragraph" data-to-manipulate="true">For the Elaris UF-1 trial, data shown are for 102 patients who received placebo, 103 patients who received elagolix alone, and 206 patients who received elagolix with add-back therapy. For the Elaris UF-2 trial, data shown are for 92 patients who received placebo, 94 patients who received elagolix alone, and 186 patients who received elagolix with add-back therapy.</div></div><div role="doc-footnote" data-has="label"><div class="label">§§</div><div id="core-t1fn10" role="paragraph" data-to-manipulate="true">For the Elaris UF-1 trial, data shown are for 102 patients who received placebo, 103 patients who received elagolix alone, and 206 patients who received elagolix with add-back therapy. For the Elaris UF-2 trial, data shown are for 90 patients who received placebo, 94 patients who received elagolix alone, and 185 patients who received elagolix with add-back therapy.</div></div></div></figcaption></a><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1904351_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1904351_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1904351/asset/61f9ac7a-58cb-4588-963c-10cf446f6c62/assets/images/large/nejmoa1904351_t2.jpg" height="2004" width="1879" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders" colspan="3"><span>Elaris UF-1</span></th><th class="txxr-borders" colspan="3"><span>Elaris UF-2</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Placebo<br> (N=102)</th><th class="xxxx-borders">Elagolix Alone<br>(N=104)</th><th class="xxxx-borders">Elagolix with Add-Back Therapy<br> (N=206)</th><th class="xxxx-borders">Placebo<br> (N=94)</th><th class="xxxx-borders">Elagolix Alone<br> (N=95)</th><th class="xxxr-borders">Elagolix with Add-Back Therapy<br>(N=189)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Volume of menstrual blood loss at final mo — ml<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of women with data</td><td class="xxxx-borders">102</td><td class="xxxx-borders">104</td><td class="xxxx-borders">206</td><td class="xxxx-borders">94</td><td class="xxxx-borders">95</td><td class="xxxr-borders">189</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Change from baseline — least-squares mean (95% CI)</td><td class="xxxx-borders shading">0.8<br> (−28.3 to 30.0)</td><td class="xxxx-borders shading">−221.5<br> (−249.9 to −193.1)</td><td class="xxxx-borders shading">−176.7<br> (−197.1 to −156.3)</td><td class="xxxx-borders shading">−4.3<br> (−34.5 to 26.0)</td><td class="xxxx-borders shading">−198.8<br> (−229.0 to −168.5)</td><td class="xxxr-borders shading">−168.8<br> (−189.8 to −147.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Difference from placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">−222.3<br> (−263.0 to −181.6)</td><td class="xxxx-borders">−177.5<br> (−213.3 to −141.7)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">−194.5<br> (−237.1 to −152.0)</td><td class="xxxr-borders">−164.6<br> (−201.5 to −127.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">P value<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&lt;0.001</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Suppression of bleeding during final mo<a href="#core-t2fn2" role="doc-noteref">†</a><a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Women with suppression — no./total no. (%)</td><td class="xxxx-borders shading">4/91 (4)</td><td class="xxxx-borders shading">79/94 (84)</td><td class="xxxx-borders shading">104/183 (56.8)</td><td class="xxxx-borders shading">4/85 (5)</td><td class="xxxx-borders shading">72/81 (89)</td><td class="xxxr-borders shading">105/172 (61.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Difference from placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">79.6<br> (71.13 to 88.16)</td><td class="xxxx-borders">52.4<br> (44.11 to 60.76)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">84.2<br> (75.99 to 92.37)</td><td class="xxxr-borders">56.3<br> (47.77 to 64.91)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">P value<a href="#core-t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&lt;0.001</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Volume of menstrual blood loss at 6 mo — ml</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of women with data</td><td class="xxxx-borders shading">71</td><td class="xxxx-borders shading">67</td><td class="xxxx-borders shading">132</td><td class="xxxx-borders shading">64</td><td class="xxxx-borders shading">53</td><td class="xxxr-borders shading">124</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Change from baseline — least-squares mean (95% CI)</td><td class="xxxx-borders">−2.3<br> (−28.9 to 24.4)</td><td class="xxxx-borders">−236.2<br> (−263.3 to −209.2)</td><td class="xxxx-borders">−194.7<br> (−214.0 to −175.5)</td><td class="xxxx-borders">28.5<br> (−4.3 to 61.4)</td><td class="xxxx-borders">−223.7<br> (−259.1 to −188.3)</td><td class="xxxr-borders">−198.1<br> (−221.5 to −174.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Difference from placebo (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">−234.0<br> (−271.9 to −196.1)</td><td class="xxxx-borders shading">−192.5<br> (−225.3 to −159.6)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">−252.3<br> (−300.6 to −204.0)</td><td class="xxxr-borders shading">−226.6<br> (−267.0 to −186.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">P value<a href="#core-t2fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Volume of menstrual blood loss at 3 mo — ml</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No. of women with data</td><td class="xxxx-borders">85</td><td class="xxxx-borders">83</td><td class="xxxx-borders">172</td><td class="xxxx-borders">78</td><td class="xxxx-borders">72</td><td class="xxxr-borders">157</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Change from baseline — least-squares mean (95% CI)</td><td class="xxxx-borders shading">6.1<br> (−24.1 to 36.2)</td><td class="xxxx-borders shading">−234.7<br> (−265.0 to −204.5)</td><td class="xxxx-borders shading">−192.2<br> (−213.4 to −170.9)</td><td class="xxxx-borders shading">−14.2<br> (−37.0 to 8.6)</td><td class="xxxx-borders shading">−211.1<br> (−234.6 to −187.6)</td><td class="xxxr-borders shading">−200.3<br> (−216.4 to −184.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Difference from placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">−240.8<br> (−283.5 to −198.1)</td><td class="xxxx-borders">−198.2<br> (−235.1 to −161.3)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">−196.9<br> (−229.7 to −164.1)</td><td class="xxxr-borders">−186.1<br> (−214.0 to −158.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">P value<a href="#core-t2fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&lt;0.001</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Women with baseline hemoglobin level ≤10.5 g/dl and increase from baseline of &gt;2 g/dl at 6 mo</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Percentage of women — no./total no. (%)</td><td class="xxxx-borders shading">5/31 (16)</td><td class="xxxx-borders shading">27/41 (66)</td><td class="xxxx-borders shading">32/52 (62)</td><td class="xxxx-borders shading">5/24 (21)</td><td class="xxxx-borders shading">10/25 (40)</td><td class="xxxr-borders shading">24/48 (50)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Difference from placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">49.7<br> (30.27 to 69.18)</td><td class="xxxx-borders">45.4<br> (26.90 to 63.92)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">19.2<br> (−6.0 to 44.3)</td><td class="xxxr-borders">29.2<br> (7.6 to 50.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">P value<a href="#core-t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">0.02</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Volume of menstrual blood loss at 1 mo — ml</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No. of women with data</td><td class="xxxx-borders shading">95</td><td class="xxxx-borders shading">97</td><td class="xxxx-borders shading">187</td><td class="xxxx-borders shading">88</td><td class="xxxx-borders shading">83</td><td class="xxxr-borders shading">175</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Change from baseline — least-squares mean (95% CI)</td><td class="xxxx-borders">−19.0<br> (−50.6 to 12.6)</td><td class="xxxx-borders">−209.0<br> (−240.3 to −177.8)</td><td class="xxxx-borders">−135.2<br> (−157.6 to −112.7)</td><td class="xxxx-borders">−2.1<br> (−30.2 to 26.1)</td><td class="xxxx-borders">−196.6<br> (−225.6 to −167.6)</td><td class="xxxr-borders">−127.0<br> (−146.9 to −107.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Difference from placebo (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">−190.0<br> (−234.5 to −145.6)</td><td class="xxxx-borders shading">−116.2<br> (−154.9 to −77.4)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">−194.5<br> (−235.0 to −154.1)</td><td class="xxxr-borders shading">−125.0<br> (−159.5 to −90.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">P value<a href="#core-t2fn6" role="doc-noteref">‖</a></td><td class="xbxx-borders">&nbsp;</td><td class="xbxx-borders">&nbsp;</td><td class="xbxx-borders">&lt;0.001</td><td class="xbxx-borders">&nbsp;</td><td class="xbxx-borders">&nbsp;</td><td class="xbxr-borders">&lt;0.001</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Outcomes are listed in the order of hierarchical statistical testing.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">The final month was defined as the last 28 days before and including the last treatment period visit date. If data on menstrual blood loss (measured with the use of the alkaline hematin method) that could be evaluated were available between the last treatment period visit date and the last dose date, then the last dose date was used. The missing data on menstrual blood loss in the final month were imputed with the use of multiple imputation.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">The P value was based on an analysis of covariance model with treatment as the main effect and baseline volume of menstrual blood loss as a covariate in each data set from multiple imputation.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">Suppression of bleeding indicated no bleeding, although there may have been spotting.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t2fn5" role="paragraph" data-to-manipulate="true">The P value was based on the chi-square test (or Fisher’s exact test if ≥20% of the cells in the categorical table had an expected cell count of &lt;5).</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t2fn6" role="paragraph" data-to-manipulate="true">The P value was based on a mixed model for repeated measures with treatment, month, and an interaction between treatment and month as fixed-effect factors and baseline volume of menstrual blood loss as a covariate in the comparison of each elagolix-with-add-back group with placebo.</div></div></div></figcaption></a><figcaption><div class="caption">Key Secondary Efficacy End Points.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1904351_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1904351_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1904351/asset/9a47bb06-ed79-4d84-a79f-5572e2b9c5c2/assets/images/large/nejmoa1904351_t3.jpg" height="1424" width="1435" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders" colspan="3"><span>Elaris UF-1</span></th><th class="txxr-borders" colspan="3"><span>Elaris UF-2</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Placebo<br> (N=102)</th><th class="xxxx-borders">Elagolix Alone<br> (N=104)</th><th class="xxxx-borders">Elagolix with Add-Back Therapy<br> (N=206)</th><th class="xxxx-borders">Placebo<br> (N=94)</th><th class="xxxx-borders">Elagolix Alone<br> (N=95)</th><th class="xxxr-borders">Elagolix with Add-Back Therapy<br> (N=189)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="6"><span>number (percent)</span></th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Adverse events</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Any adverse event</td><td class="xxxx-borders">71 (69.6)</td><td class="xxxx-borders">94 (90.4)<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">140 (68.0)</td><td class="xxxx-borders">59 (63)</td><td class="xxxx-borders">72 (76)</td><td class="xxxr-borders">143 (75.7)<a href="#core-t3fn3" role="doc-noteref">‡</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Any serious adverse event<a href="#core-t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">5 (4.9)</td><td class="xxxx-borders shading">3 (2.9)</td><td class="xxxx-borders shading">3 (1.5)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">4 (4)</td><td class="xxxr-borders shading">7 (3.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Any severe adverse event<a href="#core-t3fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">4 (3.9)</td><td class="xxxx-borders">9 (8.7)</td><td class="xxxx-borders">19 (9.2)</td><td class="xxxx-borders">6 (6)</td><td class="xxxx-borders">11 (12)</td><td class="xxxr-borders">17 (9.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Any adverse event leading to trial-drug discontinuation</td><td class="xxxx-borders shading">8 (7.8)</td><td class="xxxx-borders shading">10 (9.6)</td><td class="xxxx-borders shading">22 (10.7)</td><td class="xxxx-borders shading">5 (5)</td><td class="xxxx-borders shading">12 (13)</td><td class="xxxr-borders shading">16 (8.5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging01"><b>Adverse events in ≥5% of women who received elagolix with add-back therapy in either trial</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Hot flushes</td><td class="xxxx-borders shading">9 (8.8)</td><td class="xxxx-borders shading">67 (64.4)<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">42 (20.4)<a href="#core-t3fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">4 (4)</td><td class="xxxx-borders shading">41 (43)<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxr-borders shading">37 (19.6)<a href="#core-t3fn2" role="doc-noteref">†</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Nausea</td><td class="xxxx-borders">10 (9.8)</td><td class="xxxx-borders">7 (6.7)</td><td class="xxxx-borders">23 (11.2)</td><td class="xxxx-borders">9 (10)</td><td class="xxxx-borders">4 (4)</td><td class="xxxr-borders">14 (7.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Headache</td><td class="xxxx-borders shading">9 (8.8)</td><td class="xxxx-borders shading">17 (16.3)</td><td class="xxxx-borders shading">17 (8.3)</td><td class="xxxx-borders shading">5 (5)</td><td class="xxxx-borders shading">13 (14)</td><td class="xxxr-borders shading">20 (10.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Night sweats</td><td class="xxxx-borders">3 (2.9)</td><td class="xxxx-borders">28 (26.9)<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">14 (6.8)</td><td class="xxxx-borders">5 (5)</td><td class="xxxx-borders">24 (25)<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxr-borders">20 (10.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Fatigue</td><td class="xxxx-borders shading">2 (2.0)</td><td class="xxxx-borders shading">1 (1.0)</td><td class="xxxx-borders shading">14 (6.8)</td><td class="xxxx-borders shading">5 (5)</td><td class="xxxx-borders shading">3 (3)</td><td class="xxxr-borders shading">10 (5.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Dysmenorrhea</td><td class="xxxx-borders">4 (3.9)</td><td class="xxxx-borders">1 (1.0)</td><td class="xxxx-borders">13 (6.3)</td><td class="xxxx-borders">6 (6)</td><td class="xxxx-borders">0<a href="#core-t3fn3" role="doc-noteref">‡</a></td><td class="xxxr-borders">7 (3.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Metrorrhagia</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (1.0)</td><td class="xxxx-borders shading">13 (6.3)<a href="#core-t3fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">7 (3.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Nasopharyngitis</td><td class="xxxx-borders">4 (3.9)</td><td class="xxxx-borders">6 (5.8)</td><td class="xxxx-borders">10 (4.9)</td><td class="xxxx-borders">8 (9)</td><td class="xxxx-borders">4 (4)</td><td class="xxxr-borders">10 (5.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Decreased libido</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">5 (4.8)</td><td class="xxxx-borders shading">7 (3.4)</td><td class="xxxx-borders shading">2 (2)</td><td class="xxxx-borders shading">3 (3)</td><td class="xxxr-borders shading">10 (5.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">Urinary tract infection</td><td class="xbxx-borders">3 (2.9)</td><td class="xbxx-borders">3 (2.9)</td><td class="xbxx-borders">3 (1.5)</td><td class="xbxx-borders">5 (5)</td><td class="xbxx-borders">2 (2)</td><td class="xbxr-borders">12 (6.3)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">All adverse events were summarized with the use of the <i>Medical Dictionary for Regulatory Activities</i>, version 21.0, and are listed in descending order of incidence, starting with women who received elagolix with add-back therapy, then women who received elagolix alone, and then women who received placebo in Elaris UF-1, followed by women who received elagolix with add-back therapy, then women who received elagolix alone, and then women who received placebo in Elaris UF-2.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">P&lt;0.001 for the comparison with placebo, according to Fisher’s exact test.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">P&lt;0.05 for the comparison with placebo, according to Fisher’s exact test.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t3fn4" role="paragraph" data-to-manipulate="true">Serious adverse events were defined as life-threatening, resulting in hospitalization or medical or surgical intervention to prevent a serious outcome, or resulting in persistent disability or death.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t3fn5" role="paragraph" data-to-manipulate="true">The severity of each adverse event was rated by the investigators as mild, moderate, or severe.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t3fn6" role="paragraph" data-to-manipulate="true">P&lt;0.01 for the comparison with placebo, according to Fisher’s exact test.</div></div></div></figcaption></a><figcaption><div class="caption">Adverse Events.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1904351_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa1904351</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Bulun SE. Uterine fibroids. <em>N Engl J Med</em> 2013;369:1344-1355.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_2_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1904351&amp;key=10.1056%2FNEJMra1209993&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24088094/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000325111200012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Uterine+fibroids.&amp;publication_year=2013&amp;journal=N+Engl+J+Med&amp;pages=1344-1355&amp;doi=10.1056%2FNEJMra1209993&amp;pmid=24088094" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Moravek MB, Bulun SE. Endocrinology of uterine fibroids: steroid hormones, stem cells, and genetic contribution. <em>Curr Opin Obstet Gynecol</em> 2015;27:276-283.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/GCO.0000000000000185" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26107781/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000369598300006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Endocrinology+of+uterine+fibroids%3A+steroid+hormones%2C+stem+cells%2C+and+genetic+contribution.&amp;publication_year=2015&amp;journal=Curr+Opin+Obstet+Gynecol&amp;pages=276-283&amp;doi=10.1097%2FGCO.0000000000000185&amp;pmid=26107781" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. <em>Am J Obstet Gynecol</em> 2003;188:100-107.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1067/mob.2003.99" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12548202/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000180676900018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=High+cumulative+incidence+of+uterine+leiomyoma+in+black+and+white+women%3A+ultrasound+evidence.&amp;publication_year=2003&amp;journal=Am+J+Obstet+Gynecol&amp;pages=100-107&amp;doi=10.1067%2Fmob.2003.99&amp;pmid=12548202" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] symptomatic in up to 50% of affected women. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r39" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] used to quantify all bleeding end points. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. <em>BJOG</em> 2017;124:1501-1512.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/1471-0528.14640" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28296146/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000407971500008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Epidemiology+of+uterine+fibroids%3A+a+systematic+review.&amp;publication_year=2017&amp;journal=BJOG&amp;pages=1501-1512&amp;doi=10.1111%2F1471-0528.14640&amp;pmid=28296146" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] symptomatic in up to 50% of affected women. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r39" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] used to quantify all bleeding end points. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Stewart EA, Nicholson WK, Bradley L, Borah BJ. The burden of uterine fibroids for African-American women: results of a national survey. <em>J Womens Health (Larchmt)</em> 2013;22:807-816.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1089/jwh.2013.4334" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24033092/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000325136500005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+burden+of+uterine+fibroids+for+African-American+women%3A+results+of+a+national+survey.&amp;publication_year=2013&amp;journal=J+Womens+Health+%28Larchmt%29&amp;pages=807-816&amp;doi=10.1089%2Fjwh.2013.4334&amp;pmid=24033092" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r5-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] symptomatic in up to 50% of affected women. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r39" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] used to quantify all bleeding end points. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Stewart EA. Uterine fibroids. <em>Lancet</em> 2001;357:293-298.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(00)03622-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/11214143/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000166693400035" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Uterine+fibroids.&amp;publication_year=2001&amp;journal=Lancet&amp;pages=293-298&amp;doi=10.1016%2FS0140-6736%2800%2903622-9&amp;pmid=11214143" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] bleeding, which can lead to anemia. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and complications of pregnancy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] in adverse hypoestrogenic effects. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Wegienka G, Baird DD, Hertz-Picciotto I, et al. Self-reported heavy bleeding associated with uterine leiomyomata. <em>Obstet Gynecol</em> 2003;101:431-437.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12636944/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000181360500005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Self-reported+heavy+bleeding+associated+with+uterine+leiomyomata.&amp;publication_year=2003&amp;journal=Obstet+Gynecol&amp;pages=431-437&amp;pmid=12636944" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Napolitano M, Dolce A, Celenza G, et al. Iron-dependent erythropoiesis in women with excessive menstrual blood losses and women with normal menses. <em>Ann Hematol</em> 2014;93:557-563.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00277-013-1901-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24048634/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000332712600002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Iron-dependent+erythropoiesis+in+women+with+excessive+menstrual+blood+losses+and+women+with+normal+menses.&amp;publication_year=2014&amp;journal=Ann+Hematol&amp;pages=557-563&amp;doi=10.1007%2Fs00277-013-1901-3&amp;pmid=24048634" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Zimmermann A, Bernuit D, Gerlinger C, Schaefers M, Geppert K. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. <em>BMC Womens Health</em> 2012;12:6-6.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/1472-6874-12-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22448610/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000313498500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Prevalence%2C+symptoms+and+management+of+uterine+fibroids%3A+an+international+internet-based+survey+of+21%2C746+women.&amp;publication_year=2012&amp;journal=BMC+Womens+Health&amp;pages=6-6&amp;doi=10.1186%2F1472-6874-12-6&amp;pmid=22448610" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and complications of pregnancy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] is the most common intervention. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] resonance–guided focused ultrasonography). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. <em>Fertil Steril</em> 2007;87:725-736.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.fertnstert.2007.01.093" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17430732/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000245788600003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Etiology%2C+symptomatology%2C+and+diagnosis+of+uterine+myomas.&amp;publication_year=2007&amp;journal=Fertil+Steril&amp;pages=725-736&amp;doi=10.1016%2Fj.fertnstert.2007.01.093&amp;pmid=17430732" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Stewart EA. Uterine fibroids. <em>N Engl J Med</em> 2015;372:1646-1655.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_12_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1904351&amp;key=10.1056%2FNEJMcp1411029&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25901428/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000353294000010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Uterine+fibroids.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=1646-1655&amp;doi=10.1056%2FNEJMcp1411029&amp;pmid=25901428" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and complications of pregnancy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] is the most common intervention. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Levy G, Hill MJ, Beall S, Zarek SM, Segars JH, Catherino WH. Leiomyoma: genetics, assisted reproduction, pregnancy and therapeutic advances. <em>J Assist Reprod Genet</em> 2012;29:703-712.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s10815-012-9784-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22584729/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000308184900002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Leiomyoma%3A+genetics%2C+assisted+reproduction%2C+pregnancy+and+therapeutic+advances.&amp;publication_year=2012&amp;journal=J+Assist+Reprod+Genet&amp;pages=703-712&amp;doi=10.1007%2Fs10815-012-9784-0&amp;pmid=22584729" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Fuldeore MJ, Soliman AM. Patient-reported prevalence and symptomatic burden of uterine fibroids among women in the United States: findings from a cross-sectional survey analysis. <em>Int J Womens Health</em> 2017;9:403-411.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2147/IJWH.S133212" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28652819/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000403598900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Patient-reported+prevalence+and+symptomatic+burden+of+uterine+fibroids+among+women+in+the+United+States%3A+findings+from+a+cross-sectional+survey+analysis.&amp;publication_year=2017&amp;journal=Int+J+Womens+Health&amp;pages=403-411&amp;doi=10.2147%2FIJWH.S133212&amp;pmid=28652819" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Soliman AM, Margolis MK, Castelli-Haley J, Fuldeore MJ, Owens CD, Coyne KS. Impact of uterine fibroid symptoms on health-related quality of life of US women: evidence from a cross-sectional survey. <em>Curr Med Res Opin</em> 2017;33:1971-1978.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/03007995.2017.1372107" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28836862/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000413854200009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Impact+of+uterine+fibroid+symptoms+on+health-related+quality+of+life+of+US+women%3A+evidence+from+a+cross-sectional+survey.&amp;publication_year=2017&amp;journal=Curr+Med+Res+Opin&amp;pages=1971-1978&amp;doi=10.1080%2F03007995.2017.1372107&amp;pmid=28836862" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Ghant MS, Sengoba KS, Recht H, Cameron KA, Lawson AK, Marsh EE. Beyond the physical: a qualitative assessment of the burden of symptomatic uterine fibroids on women’s emotional and psychosocial health. <em>J Psychosom Res</em> 2015;78:499-503.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jpsychores.2014.12.016" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25725565/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000352926600015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Beyond+the+physical%3A+a+qualitative+assessment+of+the+burden+of+symptomatic+uterine+fibroids+on+women%E2%80%99s+emotional+and+psychosocial+health.&amp;publication_year=2015&amp;journal=J+Psychosom+Res&amp;pages=499-503&amp;doi=10.1016%2Fj.jpsychores.2014.12.016&amp;pmid=25725565" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ, Segars JH. The estimated annual cost of uterine leiomyomata in the United States. <em>Am J Obstet Gynecol</em> 2012;206(3):211.e1-9.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ajog.2011.12.002" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22244472/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000300878600021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+estimated+annual+cost+of+uterine+leiomyomata+in+the+United+States.&amp;publication_year=2012&amp;journal=Am+J+Obstet+Gynecol&amp;pages=211.e1-9&amp;doi=10.1016%2Fj.ajog.2011.12.002&amp;pmid=22244472" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and social well-being, and overall health, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] economic burden on women and society. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Fuldeore M, Yang H, Soliman AM, Winkel C. Healthcare utilization and costs among women diagnosed with uterine fibroids: a longitudinal evaluation for 5 years pre- and post-diagnosis. <em>Curr Med Res Opin</em> 2015;31:1719-1731.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1185/03007995.2015.1069738" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26153675/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000361328000011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Healthcare+utilization+and+costs+among+women+diagnosed+with+uterine+fibroids%3A+a+longitudinal+evaluation+for+5+years+pre-+and+post-diagnosis.&amp;publication_year=2015&amp;journal=Curr+Med+Res+Opin&amp;pages=1719-1731&amp;doi=10.1185%2F03007995.2015.1069738&amp;pmid=26153675" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and social well-being, and overall health, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] economic burden on women and society. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Soliman AM, Anand SB, Coyne KS, Castelli-Haley J, Snabes M, Owens CD. Examining the relationship between symptomatic burden and self-reported productivity losses among patients with uterine fibroids in the United States. <em>J Occup Environ Med</em> 2017;59:974-981.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/JOM.0000000000001105" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28692605/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000412539800016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Examining+the+relationship+between+symptomatic+burden+and+self-reported+productivity+losses+among+patients+with+uterine+fibroids+in+the+United+States.&amp;publication_year=2017&amp;journal=J+Occup+Environ+Med&amp;pages=974-981&amp;doi=10.1097%2FJOM.0000000000001105&amp;pmid=28692605" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and social well-being, and overall health, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] economic burden on women and society. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Yao X, Stewart EA, Laughlin-Tommaso SK, Heien HC, Borah BJ. Medical therapies for heavy menstrual bleeding in women with uterine fibroids: a retrospective analysis of a large commercially insured population in the USA. <em>BJOG</em> 2017;124:322-330.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/1471-0528.14383" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27770484/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000396378500028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Medical+therapies+for+heavy+menstrual+bleeding+in+women+with+uterine+fibroids%3A+a+retrospective+analysis+of+a+large+commercially+insured+population+in+the+USA.&amp;publication_year=2017&amp;journal=BJOG&amp;pages=322-330&amp;doi=10.1111%2F1471-0528.14383&amp;pmid=27770484" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. <em>Obstet Gynecol</em> 2010;116:865-875.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/AOG.0b013e3181f20177" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20859150/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000282067700011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Tranexamic+acid+treatment+for+heavy+menstrual+bleeding%3A+a+randomized+controlled+trial.&amp;publication_year=2010&amp;journal=Obstet+Gynecol&amp;pages=865-875&amp;doi=10.1097%2FAOG.0b013e3181f20177&amp;pmid=20859150" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Borah BJ, Yao X, Laughlin-Tommaso SK, Heien HC, Stewart EA. Comparative effectiveness of uterine leiomyoma procedures using a large insurance claims database. <em>Obstet Gynecol</em> 2017;130:1047-1056.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/AOG.0000000000002331" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29016510/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000417651200029" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparative+effectiveness+of+uterine+leiomyoma+procedures+using+a+large+insurance+claims+database.&amp;publication_year=2017&amp;journal=Obstet+Gynecol&amp;pages=1047-1056&amp;doi=10.1097%2FAOG.0000000000002331&amp;pmid=29016510" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Gurusamy KS, Vaughan J, Fraser IS, Best LM, Richards T. Medical therapies for uterine fibroids — a systematic review and network meta-analysis of randomised controlled trials. <em>PLoS One</em> 2016;11(2):e0149631-e0149631.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r22-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0149631" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26919185/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000371274400030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Medical+therapies+for+uterine+fibroids+%E2%80%94+a+systematic+review+and+network+meta-analysis+of+randomised+controlled+trials.&amp;publication_year=2016&amp;journal=PLoS+One&amp;pages=e0149631-e0149631&amp;doi=10.1371%2Fjournal.pone.0149631&amp;pmid=26919185" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r22-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r22-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with symptomatic fibroids are limited. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in adverse hypoestrogenic effects. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. <em>Hum Reprod Update</em> 2016;22:665-686.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/humupd/dmw023" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27466209/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000388934600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Uterine+fibroid+management%3A+from+the+present+to+the+future.&amp;publication_year=2016&amp;journal=Hum+Reprod+Update&amp;pages=665-686&amp;doi=10.1093%2Fhumupd%2Fdmw023&amp;pmid=27466209" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Carr BR, Marshburn PB, Weatherall PT, et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. <em>J Clin Endocrinol Metab</em> 1993;76:1217-1223.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1210/jc.76.5.1217" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/8496313/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1993LD04500023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=An+evaluation+of+the+effect+of+gonadotropin-releasing+hormone+analogs+and+medroxyprogesterone+acetate+on+uterine+leiomyomata+volume+by+magnetic+resonance+imaging%3A+a+prospective%2C+randomized%2C+double+blind%2C+placebo-controlled%2C+crossover+trial.&amp;publication_year=1993&amp;journal=J+Clin+Endocrinol+Metab&amp;pages=1217-1223&amp;doi=10.1210%2Fjc.76.5.1217&amp;pmid=8496313" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Ng J, Chwalisz K, Carter DC, Klein CE. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. <em>J Clin Endocrinol Metab</em> 2017;102:1683-1691.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r25-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1210/jc.2016-3845" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28323948/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000402614700030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dose-dependent+suppression+of+gonadotropins+and+ovarian+hormones+by+elagolix+in+healthy+premenopausal+women.&amp;publication_year=2017&amp;journal=J+Clin+Endocrinol+Metab&amp;pages=1683-1691&amp;doi=10.1210%2Fjc.2016-3845&amp;pmid=28323948" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r25-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r27-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and ovarian sex hormones in women. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r25-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] of the drug, owing to its short half-life. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. <em>J Clin Endocrinol Metab</em> 2009;94:545-551.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1210/jc.2008-1695" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19033369/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000263072700033" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Suppression+of+gonadotropins+and+estradiol+in+premenopausal+women+by+oral+administration+of+the+nonpeptide+gonadotropin-releasing+hormone+antagonist+elagolix.&amp;publication_year=2009&amp;journal=J+Clin+Endocrinol+Metab&amp;pages=545-551&amp;doi=10.1210%2Fjc.2008-1695&amp;pmid=19033369" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. <em>N Engl J Med</em> 2017;377:28-40.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r27-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_28_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1904351&amp;key=10.1056%2FNEJMoa1700089&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28525302/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000404730000006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+of+endometriosis-associated+pain+with+elagolix%2C+an+oral+GnRH+antagonist.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=28-40&amp;doi=10.1056%2FNEJMoa1700089&amp;pmid=28525302" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r27-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r27-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and ovarian sex hormones in women. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] consistent with its mechanism of action. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Friedman AJ, Daly M, Juneau-Norcross M, Gleason R, Rein MS, LeBoff M. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin ‘add-back’ for 2 years. <em>Hum Reprod</em> 1994;9:1618-1625.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r28-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/oxfordjournals.humrep.a138762" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/7836510/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1994PK04600007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+medical+therapy+for+leiomyomata+uteri%3A+a+prospective%2C+randomized+study+of+leuprolide+acetate+depot+plus+either+oestrogen-progestin+or+progestin+%E2%80%98add-back%E2%80%99+for+2+years.&amp;publication_year=1994&amp;journal=Hum+Reprod&amp;pages=1618-1625&amp;doi=10.1093%2Foxfordjournals.humrep.a138762&amp;pmid=7836510" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r28-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r29-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] effects, as observed in other studies. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r29-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] results of other trials of GnRH analogues. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Hornstein MD, Surrey ES, Weisberg GW, Casino LA. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. <em>Obstet Gynecol</em> 1998;91:16-24.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r29-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0029-7844(97)00620-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/9464714/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000071237300004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Leuprolide+acetate+depot+and+hormonal+add-back+in+endometriosis%3A+a+12-month+study.&amp;publication_year=1998&amp;journal=Obstet+Gynecol&amp;pages=16-24&amp;doi=10.1016%2FS0029-7844%2897%2900620-0&amp;pmid=9464714" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r29-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r29-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] effects, as observed in other studies. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r29-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] results of other trials of GnRH analogues. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">Magnay JL, Schönicke G, Nevatte TM, O’Brien S, Junge W. Validation of a rapid alkaline hematin technique to measure menstrual blood loss on feminine towels containing superabsorbent polymers. <em>Fertil Steril</em> 2011;96:394-398.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.fertnstert.2011.05.096" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21719001/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000293008700053" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Validation+of+a+rapid+alkaline+hematin+technique+to+measure+menstrual+blood+loss+on+feminine+towels+containing+superabsorbent+polymers.&amp;publication_year=2011&amp;journal=Fertil+Steril&amp;pages=394-398&amp;doi=10.1016%2Fj.fertnstert.2011.05.096&amp;pmid=21719001" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="core-r31" class="citations"><div class="citation"><div class="citation-content">Coyne KS, Soliman AM, Margolis MK, Thompson CL, Chwalisz K. Validation of the 4 week recall version of the Uterine Fibroid Symptom and Health-related Quality of Life (UFS-QOL) Questionnaire. <em>Curr Med Res Opin</em> 2017;33:193-200.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/03007995.2016.1248382" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27733082/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000392670300004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Validation+of+the+4+week+recall+version+of+the+Uterine+Fibroid+Symptom+and+Health-related+Quality+of+Life+%28UFS-QOL%29+Questionnaire.&amp;publication_year=2017&amp;journal=Curr+Med+Res+Opin&amp;pages=193-200&amp;doi=10.1080%2F03007995.2016.1248382&amp;pmid=27733082" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="core-r32" class="citations"><div class="citation"><div class="citation-content">Carr BR, Stewart EA, Archer DF, et al. Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and uterine leiomyomas: a randomized controlled trial. <em>Obstet Gynecol</em> 2018;132:1252-1264.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/AOG.0000000000002933" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30303923/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000454042600027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Elagolix+alone+or+with+add-back+therapy+in+women+with+heavy+menstrual+bleeding+and+uterine+leiomyomas%3A+a+randomized+controlled+trial.&amp;publication_year=2018&amp;journal=Obstet+Gynecol&amp;pages=1252-1264&amp;doi=10.1097%2FAOG.0000000000002933&amp;pmid=30303923" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="core-r33" class="citations"><div class="citation"><div class="citation-content">Higham JM, O’Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. <em>Br J Obstet Gynaecol</em> 1990;97:734-739.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1471-0528.1990.tb16249.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/2400752/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1990DU88800016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Assessment+of+menstrual+blood+loss+using+a+pictorial+chart.&amp;publication_year=1990&amp;journal=Br+J+Obstet+Gynaecol&amp;pages=734-739&amp;doi=10.1111%2Fj.1471-0528.1990.tb16249.x&amp;pmid=2400752" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="core-r34" class="citations"><div class="citation"><div class="citation-content">Mansfield PK, Voda A, Allison G. Validating a pencil-and-paper measure of perimenopausal menstrual blood loss. <em>Womens Health Issues</em> 2004;14:242-247.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.whi.2004.07.005" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15589775/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000225892000011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Validating+a+pencil-and-paper+measure+of+perimenopausal+menstrual+blood+loss.&amp;publication_year=2004&amp;journal=Womens+Health+Issues&amp;pages=242-247&amp;doi=10.1016%2Fj.whi.2004.07.005&amp;pmid=15589775" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="core-r35" class="citations"><div class="citation"><div class="citation-content">Reid PC, Coker A, Coltart R. Assessment of menstrual blood loss using a pictorial chart: a validation study. <em>BJOG</em> 2000;107:320-322.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1471-0528.2000.tb13225.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/10740326/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000086077300007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Assessment+of+menstrual+blood+loss+using+a+pictorial+chart%3A+a+validation+study.&amp;publication_year=2000&amp;journal=BJOG&amp;pages=320-322&amp;doi=10.1111%2Fj.1471-0528.2000.tb13225.x&amp;pmid=10740326" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="core-r36" class="citations"><div class="citation"><div class="citation-content">Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. <em>N Engl J Med</em> 2012;366:409-420.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_37_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1904351&amp;key=10.1056%2FNEJMoa1103182&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22296075/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000299724400006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ulipristal+acetate+versus+placebo+for+fibroid+treatment+before+surgery.&amp;publication_year=2012&amp;journal=N+Engl+J+Med&amp;pages=409-420&amp;doi=10.1056%2FNEJMoa1103182&amp;pmid=22296075" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">37.</div><div id="core-r37" class="citations"><div class="citation"><div class="citation-content">Simon JA, Catherino W, Segars JH, et al. Ulipristal acetate for treatment of symptomatic uterine leiomyomas: a randomized controlled trial. <em>Obstet Gynecol</em> 2018;131:431-439.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/AOG.0000000000002462" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29420395/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000428994700007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ulipristal+acetate+for+treatment+of+symptomatic+uterine+leiomyomas%3A+a+randomized+controlled+trial.&amp;publication_year=2018&amp;journal=Obstet+Gynecol&amp;pages=431-439&amp;doi=10.1097%2FAOG.0000000000002462&amp;pmid=29420395" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">38.</div><div id="core-r38" class="citations"><div class="citation"><div class="citation-content">Seitz C, Bumbuliene Ž, Costa AR, et al. Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids. <em>Contemp Clin Trials</em> 2017;55:56-62.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cct.2017.02.002" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28185997/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000397692100008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rationale+and+design+of+ASTEROID+2%2C+a+randomized%2C+placebo-+and+active+comparator-controlled+study+to+assess+the+efficacy+and+safety+of+vilaprisan+in+patients+with+uterine+fibroids.&amp;publication_year=2017&amp;journal=Contemp+Clin+Trials&amp;pages=56-62&amp;doi=10.1016%2Fj.cct.2017.02.002&amp;pmid=28185997" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">39.</div><div id="core-r39" class="citations"><div class="citation"><div class="citation-content">Melis GB, Neri M, Piras B, et al. Vilaprisan for treating uterine fibroids. <em>Expert Opin Investig Drugs</em> 2018;27:497-505.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/13543784.2018.1471134" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29718788/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000432689500007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Vilaprisan+for+treating+uterine+fibroids.&amp;publication_year=2018&amp;journal=Expert+Opin+Investig+Drugs&amp;pages=497-505&amp;doi=10.1080%2F13543784.2018.1471134&amp;pmid=29718788" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">40.</div><div id="core-r40" class="citations"><div class="citation"><div class="citation-content">Surrey E, Taylor HS, Giudice L, et al. Long-term outcomes of elagolix in women with endometriosis: results from two extension studies. <em>Obstet Gynecol</em> 2018;132:147-160.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r40"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/AOG.0000000000002675" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29889764/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000454043200047" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+outcomes+of+elagolix+in+women+with+endometriosis%3A+results+from+two+extension+studies.&amp;publication_year=2018&amp;journal=Obstet+Gynecol&amp;pages=147-160&amp;doi=10.1097%2FAOG.0000000000002675&amp;pmid=29889764" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">May 20, 2020</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2003851" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Elagolix for Fibroid-Associated Heavy Menstrual Bleeding</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 9, 2025</div><div class="nejm-widget_item"><div><span> New York City, New York</span></div><div><span>Radiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/744566/medical-director-body-imaging-radiologist-prestigious-manhattan-outpatient-facility/?query=fjwp&amp;rid=3059">Medical Director - Body Imaging Radiologist - Prestigious Manhattan Outpatient Facility</a></div></div><div class="nejm-widget_item"><div><span> Millbrook, New York</span></div><div><span>Primary Care</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/887335/primary-care-physician-millbrook-ny-75-minutes-north-of-new-york-city-/?query=fjwp&amp;rid=12925">Primary Care Physician, Millbrook, NY  (75 minutes North of New York City)</a></div></div><div class="nejm-widget_item"><div><span> Broomfield, Colorado</span></div><div><span>Chiefs / Directors / Dept. Heads</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/892130/medical-director-women-s-services-colorado-market-front-range/?query=fjwf&amp;rid=751">Medical Director Women's Services Colorado Market Front Range</a></div></div><div class="nejm-widget_item"><div><span> Detroit, Michigan</span></div><div><span>Hospitalist</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/876407/elite-travel-physician/?query=fjwf&amp;rid=4552">Elite Travel Physician</a></div></div><div class="nejm-widget_item"><div><span> Emeryville, California</span></div><div><span>Endocrinology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/876195/endocrinologist-epic-care-san-leandro/?query=fjwp&amp;rid=5696">Endocrinologist - Epic Care San Leandro</a></div></div><div class="nejm-widget_item"><div><span> Mount Kisco, New York</span></div><div><span>Psychiatry</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/853890/child-and-adolescent-psychiatrist/?query=fjwp&amp;rid=3059">Child &amp; Adolescent Psychiatrist</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128129&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Falerts%3Fpromo%3DONFQSR51%26query%3Dcm_rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dalerts23&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1904351&amp;pubId=41288736&amp;placeholderId=101337&amp;productId=1035"><img src="/sda/128129/rightRail--SpecialtyUpdates23-001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d611ad83dbaf32-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d611ad83dbaf32-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d611ad83dbaf32-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$863230711$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$863230711$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$863230711$--></div></div><div class="mlt-body"><!--?lit$863230711$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$863230711$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$863230711$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$863230711$-->Feb 18, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2008283?query=recirc_Semantic" target="_self">Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy</a></div><div class="mlt-article-authors"><!--?lit$863230711$-->A. Al-Hendy and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$863230711$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$863230711$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$863230711$-->Mar 13, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2410962?query=recirc_Semantic" target="_self">Liberal or Restrictive Transfusion Strategy in Aneurysmal Subarachnoid Hemorrhage</a></div><div class="mlt-article-authors"><!--?lit$863230711$-->S.W. English and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$863230711$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$863230711$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$863230711$-->May 16, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2313040?query=recirc_Semantic" target="_self">Andexanet for Factor Xa Inhibitor–Associated Acute Intracerebral Hemorrhage</a></div><div class="mlt-article-authors"><!--?lit$863230711$-->S.J. Connolly and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$863230711$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$863230711$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$863230711$-->Apr 11, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2308440?query=recirc_Semantic" target="_self">Trial of Early Minimally Invasive Removal of Intracerebral Hemorrhage</a></div><div class="mlt-article-authors"><!--?lit$863230711$-->G. Pradilla and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/review-article" target="_self"><!--?lit$863230711$-->Review Article</a> <span class="mlt-article-site-label"><!--?lit$863230711$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$863230711$-->Jun 05, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMra2405260?query=recirc_Semantic" target="_self">Franklin H. Epstein Lecture: The Fetal-to-Adult Hemoglobin Switch — Mechanism and Therapy</a></div><div class="mlt-article-authors"><!--?lit$863230711$-->S.H. Orkin</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa1904351?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa1904351" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1904351.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa1904351"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa1900236" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Meningococcal B Vaccine and Meningococcal Carriage in Adolescents in Australia</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa1910434" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Teprotumumab for the Treatment of Active Thyroid Eye Disease</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1904351_f1.jpg"><img src="/cms/10.1056/NEJMoa1904351/asset/2b6cce23-d938-4741-a88a-3b75de357388/assets/images/large/nejmoa1904351_f1.jpg" height="1514" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Reduction in Heavy Menstrual Bleeding in Women with Uterine Fibroids.</div><div class="notes"><div role="doc-footnote">Shown are the percentages of women who met the criteria for the primary end point (a menstrual blood loss [MBL] volume of &lt;80 ml in the final month and a ≥50% reduction in MBL volume from baseline to the final month) in the two trials. A significantly greater percentage of women who received elagolix with add-back therapy met the criteria for the primary end point than women who received placebo. The final month was defined as the last 28 days before and including the last treatment period visit date (if data on menstrual blood loss [measured with the use of the alkaline hematin method] that could be evaluated were available between the last treatment period visit date and the last dose date, then the last dose date was used). CI denotes confidence interval.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1904351_f2.jpg"><img src="/cms/10.1056/NEJMoa1904351/asset/1c2251f5-8322-49c9-9064-3c78cfc70a9d/assets/images/large/nejmoa1904351_f2.jpg" height="1789" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Mean Percent Change from Baseline to 6 Months in Bone Mineral Density.</div><div class="notes"><div role="doc-footnote">At 6 months, all the differences in the percent change in bone mineral density between the group of women who received elagolix with add-back therapy and the group of women who received placebo were not significant, whereas the differences in the percent change in bone mineral density between the elagolix-alone group and the placebo group were significant, except for the between-group difference at the femoral neck in Elaris UF-2. Statistical comparisons between the trial groups were analyzed with the use of an analysis of covariance model, with treatment as the main effect and the baseline bone mineral density value as a covariate. The 𝙸 bars indicate 95% confidence intervals. LS denotes least squares.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Key Secondary Efficacy End Points.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Adverse Events.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/382/4" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 382 No. 4</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jan 23, 2020</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1901229" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">S.N. Ladhani and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jan 23, 2020</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1910434" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Teprotumumab for the Treatment of Active Thyroid Eye Disease</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">R.S. Douglas and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jan 23, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1900236" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Meningococcal B Vaccine and Meningococcal Carriage in Adolescents in Australia</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">H.S. Marshall and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa1904351%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1904351&amp;pubId=41288736&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa1904351%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1904351&amp;pubId=41288736&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id08830327350644482" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d611ad83dbaf32-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d611ad83dbaf32-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d611ad83dbaf32-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d611ad83dbaf32-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d611ad83dbaf32-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d611ad83dbaf32-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d611ad83dbaf32-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d611ad83dbaf32-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d611ad83dbaf32-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d611ad83dbaf32-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d611ad6cbaaf32',t:'MTc0OTUyOTE1MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d611ad6cbaaf32&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" data-transactionid="uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" id="captureIFrame_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" target="captureIFrame_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" name="capture_screen"><input id="capture_signIn_js_version_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" name="js_version"><input id="capture_signIn_transactionId_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" data-capturefield="undefined" value="uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" type="hidden" class="capture_transactionId_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" name="capture_transactionId"><input id="capture_signIn_form_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" name="form"><input id="capture_signIn_flow_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" name="flow"><input id="capture_signIn_client_id_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" name="client_id"><input id="capture_signIn_redirect_uri_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" name="redirect_uri"><input id="capture_signIn_response_type_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" name="response_type"><input id="capture_signIn_flow_version_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" name="flow_version"><input id="capture_signIn_settings_version_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" name="settings_version"><input id="capture_signIn_locale_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" name="locale"><input id="capture_signIn_recaptcha_version_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_uxytvi9qxyg1uu32tavnhtu6lt3t7hu3zonvcfbh" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div><api-xbnerxwhkpwf></api-xbnerxwhkpwf><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa1904351?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=1-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div></body></html>